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0. General Introduction and Task of the Thesis 
 
The main focus of chemists is to synthesize both natural products and compounds that do not exist in 
nature and to study their physical, chemical and biological properties. This is accompanied by a deep 
understanding of the fundamental principles of chemical structure and reactivity and lead to the 
development of modern pharmaceutical and chemical industries. Natural products play an important role 
in the discovery and development of pharmacologically relevant compounds (drug-like compounds) and 
drugs which are actually used in the clinic. In this context, it is important to find new lead structures for 
drug discovery and to develop new synthetic methods or strategies for their assembly.1 Besides natural 
products, synthetic compounds, which do not resemble natural products, also play a key role in 
pharmacology. In recent times, the tremendous improvements in synthetic methodology have provided a 
convenient access to a great variety of synthetic substances like antibiotic, anti-infective, anti-cancer and 
cardio-vascular agents etc. 
 
Natural products often represent lead structures in drug discovery.2 Various natural products have 
been reported to show antibiotic activity. Since the discovery of penicillin, a large number of antibiotics 
have been isolated from of microorganisms.3 Anti-infective compounds are obtained from both animals 
and plants. The development of new drugs includes synthetic and semi-synthetic studies, microbial 
transformations, the biological screening and the study of the mechanism of action.4 The effort to design 
better anti-malaria agents for prophylaxis has also led to the discovery of a class of synthetic products, 
such as Malarone. 
 
Natural products have provided a great contribution to the chemotherapy of cancer. A number of 
anticancer drugs are isolated from plants or microorganisms.5 This includes bleomycin, doxorubicin, 
mitomycin, paclitaxel (TaxolTM); examples of semi-synthetic derivatives of natural products, which are 
important anticancer drugs are, Ironotecan (a camptothecin derivative), etoposide or tenoposide (a 
podophyllotoxin derivative). Currently, both a semi-synthetic derivative with improved water solubility, 
docetaxel (TaxoteneTM) and paclitaxel (TaxolTM) are approved and used clinically in the treatment of 
ovarian breast cancers. In this context, it is important to note, that the biological activity of synthetically 
modified natural products is often better than the activity of the natural products themselves. 
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The combination of medicinal chemistry and synthetic chemistry is a good tool for the development 
of new drugs. In this context, the generation of compound libraries by combinatorial chemistry and 
parallel synthesis provides a pool for screening.6 
 
Task of my thesis 
My own studies, which are outlined in this thesis, are focused on the development of new and reliable 
synthetic strategies and their application to the preparation of pharmacologically relevant carba- and 
heterocycles.  
 
In the first chapter, I had the task to develop a new application of formal [3+3] cyclization reactions 
which have been extensively studied before in the group of Prof. Langer. The plan was to develop an 
approach to sterically encumbered biaryls by combination of a recently developed Cu-catalyzed 
coupling reactions of 1,3-diketones with aryl halides with formal [3+3] cyclizations of 1,3-bis(silyloxy)-
1,3-butadienes. 
 
Chapters 2, 3, and 4 of my thesis deal with new synthetic applications of palladium(0)-catalyzed 
cross-coupling reactions. In recent years, the group of Prof. Langer has been studying Pd(0)-catalyzed 
cross coupling reactions of polyhalogenated arenes and heterocycles. In this context, the issue of site-
selectivity (regioselectivity) plays an important role. I have studied the synthesis of arylated pyrazoles, 
bis(diaryl)sulfones, and di(alkenyl)pyridines by Suzuki and Heck reactions of tribrominated pyrazoles, 















A significant part of the present dissertation has been recently published. Therefore, parts of the content 
of the publications were used for the present thesis. The thesis can be summarized as follows: 
 
1. Synthesis of sterically encumbered biaryls based on a Cu(1)-catalysed arylation / [3+3] 
cyclocondensation strategy. This chapter deals with synthesis of sterically encumbered biaryls by 
combination of CuI / proline-catalyzed arylation to give 3-arylpentan-2,4-diones. The [3+3] 
cyclocondensation of the silyl enol ethers of the latter with 1,3-bis(trimethylsilyloxy)-1,3-dienes 
afforded the sterically encumbered, functionalized biaryls. 
 
2. Synthesis of arylated pyrazoles by site-selective Suzuki-Miyaura reactions of N-protected 
tribromopyrazoles. This chapter deals with the synthesis of 3,4,5-triarylpyrazoles, 3,5-diaryl-4-
bromopyrazoles, and 5-aryl-3,4-dibromopyrazoles by reaction of N-protected 3,4,5-tribromopyrazoles 
with one, two and three equivalents of arylboronic acids by Suzuki-Miyaura reactions.    
 
3. Synthesis of bis(diaryl)sulfones by Suzuki-Miyaura reactions of 2,4-
bis(trifluoromethylsulfonyloxy)diphenylsulfone. This chapter deals with synthesis of 2,4-
bis(aryl)diphenylsulfones by reaction of 2,4-bis(trifluoromethylsulfonyloxy)diphenylsulfone with two 
equivalents of aryl boronic acids. One equivalent of boronic acid gives 2-(trifluorosulfonyloxy)-4-
arylsulfones. 
 
4 This chapter deals with the synthesis of novel bis(alkenyl)pyridines by double Heck cross 
coupling reactions of dibrominated pyridines. The Heck reaction of 2,5-dibromopyridine unexpectedly 
afforded 5,5′-bis(alkenyl)-2,2′-bipyridines by palladium-catalyzed dimerization to give 5,5′-dibromo-








1 Synthesis of Sterically Encumbered Biaryls based on a Copper(I)-Catalyzed 




Sterically encumbered biaryls are found in several natural products. These biaryls are of considerable 
importance in pharmacology. The simple biaryl cynandione A was isolated from Cynachum wilfordii. 
Cynandione A was shown to protect cultured cortical neurons from toxicity of H2O2, L-glutamate and 
kainate.7 Cynandione A-C are effective against hepatocytes, human bladder carcinoma T-24 cells, 
epidermoid carcinoma KB cells, and  human hepatoma PLC/PRF/5 cells.8 3-Arylbenzoates are also 
present in many flavones (e.g. 2,3-dihydroamentoflavone, obtained from selagenella tamariscina, which 
is active against type-2 diabetes and obesity.9a Bartramiaflavone,9b robustaflavone, obtained from 
selagenella dicatula, is effective against hepatitis B.9c Dichamanetin, obtained from U. chamae, is 
effective against gram positive bacteria.9d,e For some derivatives, inhibition of the human liver cathepsin 
B and K has been reported.9f,g Anastatin A, which was isolated from anastatica heirochuntica,10 
possesses a benzofuran moiety and shows hepativeprotective activity.11 Many pharmacologically active 
biaryl natural products, such as picropodophyllone, can be formally regarded as sterically encumbered 
4-arylphenols.12 Others, such as dioncophylleine A, contain a naphthalene and an isoquinoline moiety.13 
Flavidine may be regarded as a  complex bridged biaryl derivative.14 
Sterically encumbered biaryls are readily available by Pd(0)-catalyzed cross-coupling reactions (e.g., 
Suzuki reactions).15 Despite the usefulness of this approach, the synthesis of sterically encumbered and 
functionalized products can be sometimes difficult. Recently, a number of new ligands have been 
developed which allow to tackle these problems.16 But the regioselective preparation of the 
corresponding aryl halides, which have to be usedf as educts, is still a difficult problem in many cases. 
Arenes are alternatively available by using dienes in cyclisation reactions. For example, Chan et al. 
developed17 a convenient approach to salicylates by [3+3] cyclizations18 of with 3-trimethylsilyloxy-2-
en-1-ones with 1,3-bis(trimethylsilyloxy)-1,3-dienes.19 I have studied the synthesis of sterically 
encumbered and functionalized biaryls by a combination of CuI-proline-catalyzed arylation reactions 
and [3+3] cyclizations.  
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1.2 Results and discussion 
 
The CuI-proline-catalyzed arylation20 of 1,3-diketone 1a with aryl iodides 2a-c afforded the 2-aryl-1,3-
diketones 3a-c in 85-90% yield (Scheme 1, Table 1). Aryl iodides 2a-c were prepared by a method 
reported by He et al..21 The silylation of 3a-c gave the 3-silyloxy-2-en-1-ones 4a-c. The known 1,3-
bis(silyloxy)-1,3-dienes 5a-l were prepared in two steps from the corresponding β-ketoesters.10 The 
TiCl4-mediated [3+3] cyclocondensation of 2-aryl-3-silyloxy-2-en-1-ones 4a-c with 5a-l  afforded the 
biaryls 6a-z (Scheme 2, Table 2). During the optimization, it turned out that the reactions proceed very 
well in a highly concentrated solution. The reaction of 4a with 1,3-bis(silyloxy)-1,3-butadienes derived 
from acetylacetone and benzoylacetone proved to be unsuccessful. This can be explained their lower 
reactivity compared to dienes derived from β-ketoesters. The nature of the aryl group of enones has a 
small influence on the yield of the cyclization reactions. N-Butyl substituted enones gave comparatively 
lower yield. 
 
The substitution pattern of dienes has a strong influence on the yields. The best yields were obtained for 
products derived from non-substituted diene 5a which is derived from methyl acetoacetate. This might 
be explained by cleavage of the benzyl ester moiety by TiCl4. Since both dienes are closely related with 
respect to their structure, this result indicates that the individual quality of the diene and reagents 
employed also have a strong influence.  
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a) The dienes electrophiles must be entirely pure and distilled.  
b) The dienes must be free of polymeric impurities and monosilyl enol ether. 
c)  The TiCl4 employed must not be old.  
Chromatographic purification also plays an important role. The yields of the products derived from 4-
substituted dienes are often slightly lower than the yields of the products derived from 5a. 
The structures of 6b and 6v were independently confirmed by X-ray crystal structure analyses (Figures 1 
and 2).22 The two aryl moieties are twisted out of plane. An intramolecular hydrogen bond OH···O is 





















Scheme 1. Synthesis of 4a-c, i: K2CO3, CuI 10 mol %, L-proline 20 mol%, DMSO, 90 °C, 6-12 h; ii: 
Me3SiCl, NEt3, C6H6, 20 °C, 72 h 
 
 





        Table 1: Synthesis of 3-aryl-1,3-diketones 3a-c and 3-silyloxy-2-en-1-ones 4a-c 
1 2 3,4 R1 % (3) a % (4) a 
a a a H 76 90 
a b b Me 82 88 
a c c nBu 83 85 



















4a-c 6a-z  
               
                              Scheme 2. Synthesis of 6a-z; i: TiCl4, CH2Cl2, –78 → 20 °C, 20 h 
 
 
          Table 2. Synthesis of biaryls 6a-z 
4 5 6 R1 R2 R3 % (6)a 
a a a H Me H 61 
a b b H Et H 40 
a c c H CH2Ph H 35 
a d d H Me Me 48 
a e e H Me Et 53 
a f f H Me (CH2)2Ph 38 
 15
a g g H Me nPent 50 
a h h H Me nHex 46 
a i i H Me (CH2)2CH=CH2 48 
a j j H Me Cl 37 
b a k Me Me H 54 
b b l Me Et H 40 
b d m Me Me Me 41 
b e n Me Me Et 46 
b f o Me Me (CH2)2Ph 36 
b h p Me Me nHex 42 
c a q nBu Me H 52 
c b r nBu Et H 45 
c c s nBu CH2Ph H 38 
c d t nBu Me Me 58 
c e u nBu Me Et 55 
c f v nBu Me (CH2)2Ph 37 
c h x nBu Me nHex 48 
c k w nBu Me nNon 42 
c l y nBu Me Allyl 55 
c i z nBu Me (CH2)2CH=CH2 53 










































In short, I prepared various sterically encumbered biaryls by CuI-proline catalysed 




2. Syntheses of Arylated Pyrazoles by Site-Selective Suzuki- Miyaura 
Reactions of N-Protected 3,4,5-Tribromo-1-H-pyrazoles 
 
2.1  Introduction to palladium(0)-catalyzed reactions 
 
Palladium (Pd) is one of the most versatile and useful metals in modern organic 
synthesis.23,24 Palladium-catalyzed reactions have been applied to the synthesis of 
natural products, polymers, agrochemicals, and pharmaceuticalsImportant Pd(0)-
catalyzed reactions include the Heck reaction, Suzuki-Miyaura reaction, Stille 
reaction, the Buchwald-Hartwig reaction, and the Tsuji-Trost allylation. The well-
known Wacker reaction is a Pd(II) catalyzed process.25  
The mechanism of the Suzuki and of the Stille reaction is depicted in Scheme 3. 27 It 
includes an oxidative addition, transmetallation and reductive elimination. For Suzuki 
reactions, boronic acids or esters are used as the reagent R-M. For Stille reactions, 
organotin compounds are employed. 
 
 
Scheme 3. General mechanism for Suzuki and Stille cross-coupling reaction (this 
scheme was copied from Tetrahedron, 2005, 61, 2245). 
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The Suzuki reaction was first reported by Akira Suzuki and his group in 1979.26 The 
broad applicability of Suzuki reaction relies on the following facts.  
(1)  Commercial availability of large number of boronic acids. 
(2)  Mild reaction conditions. 
(3)  Low toxicity of reagents. 
(4)  Easy separation of inorganic by-products from reaction mixture. 
(5)  Tolerance to a broad range of functional group. 
 
The rate of Suzuki reaction depends upon the oxidative addition and transmetallation. 
The oxidative addition depends upon the reactivity of substrate. The order of 
reactivity of substrate is Ar-I> Ar-Br = Ar-OTf > Ar-Cl. The rate of transmetallation 
is increased by base. This can be explained by the increase in nuleophilicity of 
organoborane compounds by the formation of organoborate which contains a 
tetravalent boron atom.  
The catalyst plays an important role in Suzuki reactions. Very often Pd(OAc)2, PdCl2, 
Ph(PPh3)Cl2, and Pd(dba)2 are employed. Bulky electron-rich ligands often give 
excellent results, such as ferrocenylphos28, N-heterocyclic carbenes,29 P(tBu)330, 
P(Cy)3 and others. 
Suzuki reaction have been applied to several physically or biologically relevant 
systems, such as NLO-active 1,8-diarylnapthalenes,31 non-natural amino acids,32 anti 
HIV compounds,33 potent antibiotics such as vancomycin,34 carbon nanotubes,3 and 
even solar cells.36 
 
The Heck reaction was developed by Mizoroki and Heck in the early 1970s. The 
Heck reaction is the palladium catalysed cross-coupling reaction of organohalides or 
triflates with alkenes in the presence of a base.37, 38 Generally the rate of reaction of 
more substituted olefins is slower than the rate of reaction of less substituted olefins. 
Typically the order of reaction of organohalides is as follows  I > Br ~ OTf >> Cl 
The mechanism of the Heck reaction is similar to the Suzuki reaction, but the C-C 
bond formation is established by carbapalladation of the alkene instead of 







2.2 Introduction to pyrazole syntheses 
 
Five-membered heterocyclic compounds are of synthetic relevance, due to their 
biological properties. Pyrazoles show a variety of pharmacological effects which 
include anti-inflammatory42, antiobiotic43, alcohol dehydrogenase inhibitory 
activity,44 activity as nicotinic acid receptor agonists,45a and activity as excitory amino 
acid antagonists.45b, 45c The drug celecoxib, which exhibits anti-inflammatory 
properties, is used to treat arthritis, minstrel cramps and colonic polyps.45d,e Recently, 
Nicolaou and coworkers45f studied the anticancer activity of epothilone A and B, 
which also contain a pyrazole moiety.  
Pyrazoles are synthetically available by 1,3-dipolar cycloaddition reactions of 
diazoalkanes with alkynes and related transformations.46 A classic approach to 
pyrazoles relies on the cyclisation of hydrazines with 1,3-diketones or ,-
unsaturated ketones.47 lternatively, hydrazone dianions have been cyclized with 
various carboxylic acid derivatives.48 Noteworthy, some COX-1 and COX-2 inhibitors 
were prepared by reaction of hydrazine with 4-aryl-2,4-dioxoesters. 49  
 
 
2.3   Results and discussion 
 
The field of site-selective palladium catalysed cross-coupling reactions of 
polyhalogenated heterocycles is of great interest nowadays because these reactions 
often provide a facile and site-selective approach to highly substituted 
heterocycles.50,51 This approach relies on substitution reactions of the heterocyclic 
core rather than on its assembly as described in the introduction (see above). When I 
started my work, palladium-catalyzed cross-coupling reactions of polyhalogenated 
pyrazoles had, to the best of my knowledge, not been reported. Recently, metal-halide 
exchange reactions of N-vinyl-tribromopyrazole were reported.52 Together with my 
colleagues R. A. Khera and M. Hussain, I have developed Suzuki-Miyaura reactions 
of N-vinyl- and N-benzyl-tribromopyrazole. The results of my own efforts in this field 
are described in this thesis. The products, triaryl-pyrazoles, 3,5-diaryl-4-
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bromopyrazoles, and 5-aryl-3,4-dibromopyrazoles, are of considerable 
pharmacological relevance.53 Previous syntheses of these molecules are not 
straightforward and mainly include derivatives containing the same type of aryl 
moiety.  
 
N-Benzyl-tribromopyrazole (8a) was prepared from commercially available 
tribromopyrazole by modification of a known procedure (Scheme 4).54 Instead of 
benzylchloride, which was used in the original procedure, I have used benzylbromide. 
N-Vinyl-tribromopyrazole (8b) was prepared, again following a reported procedure,52 




































Scheme 4. Synthesis of 8a,b. Reagents and conditions: i,  (1.0 equiv), benzylbromide 
(1.0 equiv), NEt3 (1.1 equiv), CH2Cl2 (5 mL per mmol of 7), 20 °C, 4 h. ii, 7 (1.0 
equiv), 1, 2-dibromoethane (1.2 equiv), NEt3 (5 mL per mmol), CH3CN (5 mL per 
mmol of 7), 70 C, 7 h 
 
The Suzuki-Miyaura reaction of 8a and 8b with arylboronic acids 9a-c (1.0 equiv.) 
afforded the 5-aryl-3,4-dibromopyrazoles 10a-c in 66-73% yield (Table 3, Scheme 5). 
A good yield was obtained even for sterically hindered boronic acids. During the 
optimization, the best yields were obtained when Pd(PPh3)4 was used as the catalyst 
(3 mol %) and when K3PO4 (1.5 equiv.) was used as the base. The use of Pd(OAc)2 in 
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the presence of XPhos55 gave less yield. The use of exactly one equivalent of the 
boronic acid was crucial to avoid multiple coupling. The reactions were carried out in 
a 4:1 mixture of dioxane and water. The use of toluene was less efficient because of 
the low solubility of the boronic acids in toluene. The temperature (100 °C) and the 
reaction time (12 h) also played an important role. The formation of 10a-c proceded, 




                     
 
















Scheme 5. Synthesis of 5-aryl-3,4-dibromopyrazoles 10a-c. Reagents and conditions: 
i, 8 (1.0 equiv), ArB(OH) 2 (1.0 equiv), K3PO4 (1.5 equiv), Pd(PPh3)4 (3 mol-%), 1,4-
dioxane / H2O (4:1), 100 C, 12 h. 
 
               
                 Table 3. Synthesis of 5-aryl-3,4-dibromopyrazoles 10a-c 
8 9   10 R Ar %(10)a 
b a     a Vinyl 4-(MeO)C6H4  66 
b b      b Vinyl 2-(MeO)C6H4 69 
b c      c Vinyl 2,6(MeO)2C6H3 71 






The structure of compound 10a was established by 2D NMR using H-H (NOESY) 
and H-C (HMQC) correlations. The vinylic proton attached to carbon C-129.7 
showed a clear correlation through space with the phenyl proton located at δ 7.30 
which confirmed that the 4-methoxyphenyl is attached at C-5 of the pyrazole moiety 
























The Suzuki-Miyaura reaction of 8a and 8b with arylboronic acids 9c-d (2.0 equiv.) 
gave the 3,5-diaryl-4-bromopyrazoles 11a-d in 40-74% yield (Table 4, Scheme 6). A 
good yield was obtained even for the sterically hindered boronic acid 9d. A slightly 
increased amount of the catalyst (5 mol %), exactly two equivalents of the boronic 
acid, and the double amount of base (3.0 equiv.) were used. The yields slightly 
decreased for product 11d derived from the electron-poor boronic acid 9d and for 
product 11b derived from the sterically hindered boronic acid 9d. The structure of 11a 
was independently confirmed by X-ray crystal structure analysis (Figure 3). As 
expected, the heterocyclic moiety is flat. The aryl groups are slightly twisted out of 
















Scheme 6. Synthesis of 5-aryl-3,4-dibromopyrazoles 11a-d. Reagents and conditions: 
i, 8 (1.0 equiv), ArB(OH) 2 (2.0 equiv), K3PO4 (3.0 equiv), Pd(PPh3)4 (5 mol-%), 1, 4-
dioxane / H2O (4:1), 100 C, 12 h. 
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                  Table 4. Synthesis of 3,5-diaryl-4-bromopyrazoles 11a-d 
8 9 11 R Ar %(11)a 
b a a Vinyl 4-(MeO)C6H4 40 
b c b Vinyl 2,6-(MeO)2C6H3 62 
b d c Vinyl 3,5-(MeO)2C6H3 74 
a e d Benzyl 4-FC6H4 66 




                                       




The Suzuki-Miyaura reaction of 8a and 8b with an excess of arylboronic acids 9d,f,g 
(3.5 equiv.) afforded the 3,4,5-triaryl-pyrazoles 12a-c in 50-76% yield (Table 5, 
Scheme 7). The use of 10 mol% of catalyst, excess of boronic acid (3.5 equiv) and 
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base (4.5 equiv) gave excellent results during optimization. The yields slightly 

















Scheme 7. Synthesis of 3,4,5-triaryl-pyrazoles 12a-c. Reagents and conditions: i, 8 
(1.0 equiv), ArB(OH)2 (3.5 equiv), K3PO4 (4.5 equiv), Pd(PPh3)4 (10 mol-%), 1,4-
dioxane / H2O (4:1), 100 C, 12 h. 
 
   
 Table 5. Synthesis of 3,4,5-triaryl-pyrazoles 12a-c 
8 12 9 R Ar % (12)a


















2.4  Conclusion 
 
In conclusion, I reported site-selective Suzuki-Miyaura reactions of N-protected 
tribromopyrazoles. The reaction of the latter with three, two or one equivalents of 
arylboronic acids gave 3,4,5-triaryl-pyrazoles, 3,5-diaryl-4-bromopyrazoles, or 5-aryl-
3,4-dibromopyrazoles, respectively. The products are not readily available by other 









Diarylsulfones constitute a pharmacologically important molecular entity. Reported 
activities include antimicrobial activity,56 various enzyme inhibitions57, 58, 59 
hypolipidemic,60 cytotoxic,61 neuropetide receptor binding,62, anti HIV63, 
anticholestermic,64 muscuarinic receptor binding,65 histamine H3 receptor 
antagonistic,66 antiprotozoal,67 neuroblastemic cellbinding,68 and cannabinoid CB1 
receptor binding activity.69 
 
Diaryl sulfones are classically available by oxidation of diaryl sulfides,70 Friedel-
Crafts acylation of methoxybenzene with arylsulfoniyl chlorides,71 or by condensation 
of phenols with benzenesulfonic acid.72 These methods usually require drastic 
conditions and proceed with low o,p-regioselectivities. Diaryl sulfones have been 
prepared by CuI/proline-mediated reaction of aryl iodides with sodium 
benzenesulfinate.73 In addition, the Suzuki reaction of phenylsulfonic acid chloride 
with 4-methoxybenzeneboronic acid,74 and the Cu(OAc)2-catalyzed reaction of 4-
methoxybenzeneboronic acid with sodium benzenesulfinate have been reported.75 
Diaryl sulfones have also been prepared by cyclization reactions of sulfone-containing 
building blocks.76 In my thesis, I have developed a new approach to 
bis(diaryl)sulfones by  Suzuki-Miyaura reactions of the bis(triflate) of 2,4′-
bis(dihydroxy)diphenylsulfone. The issue of site-selectivity for these transformations 








 3.2      Results and discussion 
 
Commercially available 2,4′-bis(hydroxy)-diphenylsulfone (13) was transformed into 
its bis(triflate) 14 in 81% yield (Scheme 8). The Suzuki reaction of 14 with 
arylboronic acids 15a-i (2.6 equiv.) afforded the novel 2,4′-bis(aryl)-diphenylsulfones 
16a-i in good yields (Scheme 9, Table 6). The reactions were carried out using 
Pd(PPh3)4 (6 mol-%) as the catalyst. The employment of other catalysts, such as 
PdOAc)2/ XPhos, resulted in a decreased yield (formation of complex mixtures which 
are difficult to be separated). A slight excess (2.6 equiv.) of the boronic acid was 
used. Potassium phosphate (K3PO4) was used as the base. 1,4-Dioxane (110 °C, 4 h) 















14 (81%)  
 
Scheme 8. Synthesis of 14. Reagents and conditions: i, CH2Cl2, 13 (1.0 equiv), -78 



































Scheme 9. Synthesis of 16a-i. Reagents and conditions: i, 14 (1.0 equiv.), 15a-i (2.6 
equiv.), K3PO4 (3.0 equiv.), Pd(PPh3)4 (6 mol-%), 1,4-dioxane (5 mL per 1 mmol of 
14), 110 C, 4 h 
 
 
      Table 6. Synthesis of 2,4′-bis(aryl)diphenylsulfones 16a-i  
14,16 R1 R2 R3 R4 %(16)a 
a H H Me H 70 
b H CF3 H H 60 
c OMe H H H 62 
d H H CF3 H 65 
e H H tBu H 70 
f H H F H 55 
g H H Vinyl H 65 
h H Me H Me 60 
i H OMe H OMe 72 
                     aYields of isolated products 
 
 
The structure of 16e was independently confirmed by X-ray crystal structure analysis 





                                  











In conclusion, I have reported a new synthesis of 2,4′-bis(aryl)diphenylsulfones by 
palladium(0)-catalyzed cross-coupling reactions of the bis(triflate) of 2,4′-











Pyridines are of relevance in medicinal chemistry and occur in a number of natural 
products. A prominent example is nicotinic acid and its derivatives, vitamin B6 and 
various other molecules.77,78 The research group of Prof. P. Langer has reported the 
synthesis and biological evaluation of 2-sulfonylpyridines79 and 4-hydroxy-4-
(pyridyl)alk-3-en-2-ones80 which exhibit anti-microbial activity. The class method of 
preparation of pyridine derivatives relies on base-mediated cyclocondensation 
reactions, e. g., the Hantzsch reaction.78,81,82. Although these methods have great 
utilities but in case of specific substitution pattern and labile functionalities these 
methods are not so successful. To overcome these problems palladium-catalyzed 
cross-coupling reactions to halogenated pyridines can be advantageous. As mentioned 
in chapter 3, various site-selective reactions of polyhalogenated heterocycles have 
been previously studied.83, Cross-coupling reactions of halogenated pyridines have 
also been reported.  2,5-Dibromopyridine has been used in aminations,84 and in 
Stille,85 Suzuki,86 Negishi,87 Sonogashira,88 and Kumada couplings.89 In all cases, the 
first reaction occured at the more electron-deficient position C-2. In most studies, 
single coupling reactions were carried out. Recently, Handy and coworkers reported 
the first double Suzuki couplings of 2,5- and 2,3-dibromopyridine.90 Single Heck 
coupling reactions of 2-chloro- and 2-bromopyridine have been studied in recent 












 4.2    Results and discussion 
 
The Heck reaction of 2,3-dibromopyridine (17a) with acrylates 18a-e afforded the 
2,3-di(alkenyl)pyridines 19a-e (Table 7). The reaction of 17a with styrenes 18f-i gave 
products 19f and 19h-i (19g could not be isolated, due to decomposition during the 
reaction). All products 19a-i were isolated in 60-84% yield and contain exclusively E-
configured double bonds. The reaction of 18f and 18i with 2,3-dichloropyridine (17b) 
instead of 17a afforded 19f and 19i, albeit, in only poor yields. The reaction 
conditions were thoroughly optimized for the synthesis of 19c and 19f (Scheme 10, 
Table 10). The best yields were obtained when the reactions were carried out using 
17a, Pd(OAc)2 (5 mol-%) and the biaryl monophosphine ligands SPhos (L1, for 19a-
g,i) or XPhos (L2, for 19h) (10 mol-%) which were both recently developed by 
Buchwald and coworkers. The use of tricyclohexylphosphane (L4) gave slightly lower 
yields. The employment of Pd(PPh3)4 resulted in considerably lower yields. 
Trietylamine was used as the base in all reactions. The application of other bases 
(K2CO3) did not result in an increase of the yield. The reactions were carried out in 
DMF at 120 °C. A relatively long reaction time (48 h) was necessary to achieve a 
complete conversion. Recently, Li and Wang reported92 that triethanolamine (L3) 
represents an efficient and reusable combined base, ligand, and solvent for Heck 













17a (X = Br)




Scheme 10. Conditions: i, Pd (OAc)2 (5 mol-%), L1 (10 mol-%), NEt3, DMF, 120 ˚C, 
48 h 
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                        Table 7. Synthesis of 2,3-di(alkenyl)pyridines 19a-i 
17 18 R %(19)a 
a a CO2Me 63 
a b CO2Et 71 
a c CO2iBu 82 
a d CO2tBu 84 
a e CO2CO2b 60 
a f CO2Rb 72 
b f Ph 11 
a g Ph 0c 
a h 4-(tBuO)C6H4 79 
a i 4-(MeO)C6H4 65 
b i 4-MeC6H4 9 
 






















The Heck reaction of 2,5-dibromopyridine (20) with acrylates 18c-e,i-k gave the 
5,5′-di(alkenyl)-2,2′-bipyridines 21a-f in 60-84% yields instead of the expected 
bis(alkenyl)pyridines (Table 8). The best yields were obtained using Pd(OAc)2 and 
L2. The synthesis of 2,5-di(alkenyl)pyridines by double Heck reaction was not 
possible under various conditions (different catalysts and temperatures). The 
formation of 21a-f can be explained by palladium-catalyzed dimerization to give 
5,5′-dibromo-2,2′-bipyridine and subsequent twofold Heck reaction. The 
palladium-catalyzed dimerization seems to be faster than the Heck reaction. The 
formation of 2,2′-bipyridine as a side product in Heck reactions of 2-
bromopyridine has been previously noted.  
 
The structure of 21d was independently confirmed by X-ray crystal structure 













Scheme 11. Conditions: i, Pd(OAc)2 (5 mol-%), L2 (10 mol-%), NEt3, DMF, 120 
˚C, 48 h. 
   
 








                                                    

























                                           aYields of isolated products. 
 34
  
                               Figure 5. Ortep plot of 21d (50% probability). 
 
 
The double Heck reaction of 3,5-dibromopyridine (22) with acrylates 18a-d,f,i-k, 
using Pd(OAc)2 and L4, afforded the 3,5-di(alkenyl)pyridines 23a-h in 69-84% 
yields (Scheme 12, Table 9). Similar yields were obtained using ligands L4 and L1 














                             












                                           
 
 
                                 aYields of isolated products. 
18 23   R % (23) a

















d f CO2tBu 81 
f g Ph 72 
i h 4-MeC6H4 76 
 
 
Table 10. Optimization of the synthesis of 3,5-di(alkenyl)pyridines 23c,f 






Pd(PPh3)4 (5 mol-%), NEt3, DMF, 120 ˚C, 48 h 38 49 
Pd(OAc)2 (5 mol-%), PCy3(10 mol-%), NEt3, DMF, 120 ˚C,48h 72 63 
Pd(OAc)2 (5 mol-%), L1 (10 mol-%), NEt3, DMF, 120 ˚C, 48 h 82 72 
Pd(OAc)2 (5 mol-%), L2 (10 mol-%), NEt3, DMF, 120 ˚C, 48 h 80 69 
Pd(OAc)2 (5 mol-%), N(CH2CH2OH)3 (3 mL), 120 ˚C, 48 h 2 10 










4.3  Conclusions 
 
In conclusion, I have reported the first double Heck cross-coupling reactions of 2,3-
2,5- and 3,5-dibromopyridine with various alkenes. These reactions afforded the 
corresponding bis(alkenyl)-pyridines. The Heck reaction of 2,5-dibromopyridine gave 
5,5′-bis(alkenyl)-2,2′-bipyridines by palladium-catalyzed dimerization and subsequent 






















 5. Abstract 
 
Sterically encumbered biaryls were prepared by combination of [3+3] 
cyclocondensation reactions with the arylation of acetylaceton in the presence of 
catalytic amounts of CuI and L-proline (Scheme I). 
3,4,5-Triarylpyrazoles, 3,5-diaryl-4-bromopyrazoles and 5-aryl-3,4-dibromopyrazoles 
were prepared by the Suzuki-Miyaura reactions of  N-protected 3,4,5-
tribromopyrazoles. The reactions proceeded with very good site-selectivity (Scheme 
II). 
Bis(diaryl)sulfones were prepared by Suzuki reaction of the bis(triflate) of 2,4-
bis(hydroxyl)-diphenylsulfone (Scheme III). 
Heck cross-coupling reactions of 2,3- and 3,5-dibromopyridine with various alkenes 
afforded the corresponding novel bis(alkenyl)pyridines (Scheme IV). The Heck 
reaction of 2,5-dibromopyridine unexpectedly afforded 5,5′-bis(alkenyl)-2,2′-
bipyridines by palladium-catalyzed dimerization to give 5,5′-dibromo-2,2′-bipyridine 










































































































22 24[Pd]  
 
 Scheme IV. Heck reactions of dibrominated pyridines  
     
 
 
Abstract in German 
Sterisch gehinderte Biaryle wurden durch Kombination von [3+3] Cyclocondensation 
mit der Arylierung von Acetylaceton in Gegenwart katalytischer Mengen von CuI und 
L-Prolin (Schema I). 
3,4,5-Triarylpyrazole, 3,5-Diaryl-4-bromopyrazole und 5-Aryl-3,4-dibromopyrazole 
wurden durch Suzuki-Miyaura Reaktionen von  N-geschützten 3,4,5-
Tribromopyrazolen hergestellt. Die Reaktionen laufen mit sehr gutter 
Regioselektivität ab (Schema II). 
Bis(diaryl)sulfone wurden durch Suzuki Reaktionen von Bis(triflaten) von 2,4-
Bis(hydroxyl)-diphenylsulfonen hergestellt (Schema III). 
 40
Die Heck Kreuzkupplung von 2,3- und 3,5-Dibromopyridinen mit verschiedenen 
Alkenen lieferte die entsprechenden Bis(alkenyl)pyridine (Schema IV). Die Heck 
Reaktion von 2,5-Dibromopyridin lieferte überraschend 5,5′-Bis(alkenyl)-2,2′-
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6          Experimental Section 
 
6.1  General: Equipment, chemicals and work technique 
 
1H NMR Spectroscopy:  
Bruker: AM 250, Bruker ARX 300, Bruker ARX 500; δ = 0.00 ppm for 
Tetramethylsilane; δ = 2.04 ppm for acetone-d6; δ = 7.26 ppm for (CDCl3); 2.50 ppm 
for DMSO- d6; characterization of the signal multiplicity: s = singlet, d = doublet, dd 
= double of doublet, ddd = doublet of a double doublet, t = triplet, q = quartet, quint = 
quintet; sext = Sextet, sept = Septet, m = multiplet, br = broadly. Spectra were 




13C NMR Spectroscopy 
 
 Bruker: AM 250, (62.9 MHz); Bruker: ARX 300, (75 MHz), Bruker: ARX 500, 
(125 MHz) Ref: 29.84 ± 0.01 ppm and 206.26 ± 0.13 ppm for (CD3)2CO. δ = 128.00 
ppm for acetone-d6; δ = 77.00 ppm for CDCl3. The multiplicity of the carbon atoms 
was determined by the DEPT 135 and APT technique (APT = Attached Proton Test) 
and quoted as CH3, CH2, CH and C for primary, secondary, tertiary and quaternary 
carbon atoms. Characterization of the signal fragmentations: quart = quartet the 
multiplicity of the signals was determined by the DEPT recording technology and/or 









High Resolution mass spectroscopy 
 
Finnigan MAT 95 or Varian MAT 311; Bruker FT 
CIR, AMD 402 (AMD Intectra). 
 
Infrared spectroscopy (IR):  
Bruker IFS 66 (FT IR), Nicolet 205 FT IR; Nicolet Protege 460, Nicolet 360 
Smart Orbit  (ATR); KBr, KAP, Nujol, and ATR; Abbreviations for signal 




LECO CHNS-932, Thermoquest Flash EA 1112. 
 
X-ray crystal structure analysis 
 
Bruker X8Apex Diffractometer with CCD-Kamera (Mo-Ka und Graphit 




Micro heating table HMK 67/1825 Kuestner (Büchi apparatus); Melting 




Chromatography was performed over Merck silica gel 60 (0,063 -0,200 mm, 70 - 230 
mesh) as normal and/or over mesh silica gel 60 (0,040 - 0,063 mm, 200 -400 mesh) as 









Merck DC finished foils silica gel 60 F254 on aluminum foil and Macherey finished 
Foils Alugram® Sil G/UV254. Detection under UV light with 254 nm and/or 366 nm 
without dipping reagent, as well as with anisaldehyde sulfuric acid reagent (1 mL 
anisaldehyde consisting in 100 mL stock solution of 85% methanol, 14% acetic acid 
and 1% sulfuric acid). 
 
Chemicals and work technique 
  
All solvents for using were distilled by standard methods. All reactions were carried 
out under an inert atmosphere, oxygen and humidity exclusion. All of the chemicals 
are standard, commercially available from Merck®, Aldrich®, Arcos® and others. The 
order of the characterized connections effected numerically, but does not correspond 





















6.2      Procedures and spectroscopic data 
 
Typical procedure for the synthesis of 2-aryl-1,3-diones (3a-c) 
 
 A DMSO solution (2 mL) of 1a (1.5 mmol), 2a-c (0.5 mmol), K2CO3 (2.0 mmol), 
CuI (0.05 mmol), L-proline (1.0 mmol) was stirred at 90-120 °C under Argon 
atmosphere for 6-12 h. The cooled solution was poured into 1.0 M HCl and extracted 
with EtOAc. The combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated in vacuo. The residue was purified by chromatography 









 Starting with 1a (7.7 mL, 75.0 mmol), 2a (2.7 mL, 25.0 mmol), K2CO3 
(13.8 g, 100.0 mmol), CuI (0.47 g, 10 mol%), L-proline (0.57 g, 20 
mol%) and 100 mL of DMSO (heating for 6 h at 90 °C), 3a was obtained 
as a pale yellow oil (3.18 g, 76%). 1H-NMR (300 MHz, CDCl3, enol):  
= 1.93 (s, 6H, CH3), 6.99 (d (br.), 2H, J = 6.8 Hz, HAr), 7.23-7.34 (m, 3H, HAr); 13C-
NMR (75 MHz, CDCl3):  = 24.3 (CH3), 114.3 (C, enol form), 125.5 (CHPh), 127.3 
(2CHPh), 128.8 (2CHPh), 134.2 (CAr), 190.8 (C=O). 
O O
 
3-p-Tolylpentane-2,4-dione (3b)  
Starting with 1a (7.7 mL, 75.0 mmol), 2b (5.4 g, 25.0 mmol), K2CO3 
(13.8 g, 100.0 mmol), CuI (0.47 g, 10 mol%), L-proline (0.57 g, 20 
mol%) in 100 mL of DMSO (heating for 9 h at 90 °C), 3b was obtained 
as a colorless solid (3.86 g, 82%). 1H-NMR (300 MHz, CDCl3, enol):  = 
1.99 (s, 6H, CH3), 7.08 (d (br.), 2H, J = 7.7 Hz, HAr), 7.17 (d (br.), 2H, J 
O O
 46
= 7.7 Hz, HAr); 13C-NMR (75 MHz, CDCl3):  = 21.7, 24.2 (CH3), 114.7 (C, enol 
form), 129.2 (2CHAr), 129.5 (2CHAr), 135.1, 136.2 (CAr), 191.4 (C=O). 
 
3-(4-Butylphenyl)pentane-2,4-dione (3c) 
Starting with 1a (9.4 mL, 92.22 mmol), 2c (5.1 mL, 30.75 mmol), K2CO3 
(17.04 g, 123.03 mmol), CuI (0.585 g, 10 mol%), L-proline (0.708 g, 20 
mol%) in 123 mL of DMSO (heating for 10 h at 120 °C), 3c was 
obtained as a viscos yellowish oil (5.93 g, 83%). 1H-NMR (300 MHz, 
CDCl3, enol):  = 0.88 (t, 3H, J = 7.1 Hz, CH3), 1.31 (sextet, 2H, J = 7.2 
Hz, CH2), 1.58 (quintet, 2H, J = 7.8 Hz, CH2), 1.91 (s, 6H, CH3), 2.58 (t, 
2H, J = 7.6 Hz, CH2), 6.85 (d, 2H, J = 8.2 Hz, HAr), 7.11 (d, 2H, J = 8.2 Hz, HAr); 
13C-NMR (75 MHz, CDCl3):  = 13.9 (CH3), 22.4 (CH2), 24.1 (CH3), 33.5, 35.3 
(CH2), 115.0 (C, enol form), 128.7 (2CHAr), 130.8 (2CHAr), 134.0, 142.1 (CAr), 191.0 
O O
(C=O). 
al data could not be obtained. All products were obtained as 






General procedure for the synthesis of silyl enol ethers (4a-c). 
To stirred benzene solution (2.5 mL per 1.0 mmol of 3a-c) of 3a-c (1.0 equiv.) was 
added triethylamine (1.6 equiv.). After stirring for 2 h, trimethylchlorosilane (1.8 
equiv.) was added. The solution was stirred for 72 h and, subsequently, the solvent 
was removed in vacuo and hexane (1.5 mL per 1.0 mmol of starting material) was 
added to the residue to give a suspension. The latter was filtered under argon 
atmosphere. The filtrate was concentrated in vacuo to give silyl enol ethers 4a-c, 
which were used without further purification. Due to the unstable nature of the 







3-Phenyl-4-(trimethylsilyloxy)pent-3-en-2-one (4a): Starting with benzene (42.5 
mL), 3a (3.0 g, 17.02 mmol), triethylamine (3.2 mL, 27.2 mmol) and 
trimethylchlorosilane (4.5 mL, 30.6 mmol), 4a was isolated as a 
yellowish oil (3.80 g, 90%). 1H-NMR (300 MHz, CDCl3):  = 0.21 (s, 
9H, Si[CH3]3), 2.00 (s, 3H, CH3), 2.36 (s, 3H, CH3), 6.99 (d (br.), 2H, 
3J = 6.8 Hz, HAr), 7.23-7.34 (m, 3H, HAr); 13C-NMR (75 MHz, CDCl3):  = 0.4 
(Si[CH3]3), 21.7, 23.7 (CH3), 114.6 (=C), 125.5 (CHPh), 127.3 (2CHPh), 128.8 
(2CHPh), 134.2 (CAr), 186.1 (COSi), 191.2 (C=O). 
O OTMS
 
3-p-Tolyl-4-(trimethylsilyloxy)pent-3-en-2-one (4b): Starting with benzene (31.5 
mL), 3c (2.4 g, 12.6 mmol), triethylamine (2.4 mL, 20.1 mmol) and 
trimethylchlorosilane (3.38 mL, 22.7 mmol), 4b was isolated as a slight 
yellowish oil (2.9 g, 88%). 1H-NMR (300 MHz, CDCl3):  = 0.21 (s, 
9H, Si[CH3]3), 1.93 (s, 3H, CH3), 1.98 (s, 3H, CH3), 2.34 (s, 3H, CH3), 
7.08 (d (br.), 2H, J = 7.7 Hz, HAr), 7.17 (d (br.), 2H, J = 7.7 Hz, HAr); 
13C-NMR (75 MHz, CDCl3):  = 0.4 (Si[CH3]3), 21.5, 23.8, 24.1 (CH3), 114.7 (=C), 
129.2 (2CHAr), 129.5 (2CHAr), 136.3 (CAr), 186.3 (COSi), 191.0 (C=O). 
O OTMS
 
3-(4-Butylphenyl)-4-(trimethylsilyloxy)pent-3-en-2-one (4c): Starting with benzene 
(50 mL), 3c (4.4 g, 18.9 mmol), triethylamine (3.5 mL, 30.2 mmol) and 
trimethylchlorosilane (5.0 mL, 34.2 mmol), 4c was isolated as a 
yellowish oil (4.8 g, 85%). 1H-NMR (300 MHz, CDCl3):  = 0.21 (s, 
9H, Si[CH3]3), 0.88 (t, 3H, J = 7.1 Hz, CH3), 1.31 (sextet, 2H, J = 7.2 
Hz, CH2), 1.58 (quintet, 2H, J = 7.8 Hz, CH2), 1.87 (s, 3H, CH3), 1.91 
(s, 3H, CH3), 2.58 (t, 2H, J = 7.6 Hz, CH2), 6.85 (d, 2H, J = 8.2 Hz, 
HAr), 7.11 (d, 2H, J = 8.2 Hz, HAr); 13C-NMR (75 MHz, CDCl3):  = 0.4 (Si[CH3]3), 
13.9 (CH3), 22.4 (CH2), 23.9, 24.2 (CH3), 33.5, 35.3 (CH2), 114.8 (=C), 128.7 








General procedure for the synthesis of 4-hydroxybiphenyl-3-carboxylates (6a-z). 
 To a CH2Cl2 solution (2 mL / 1.0 mmol of 5) of 5 (1.0 equiv.) was added 4 
(1.0 equiv.) and subsequently TiCl4 (1.0 equiv.) at 78 °C. The temperature of the 
solution was allowed to warm to 20 °C during 14 h with stirring. To the solution was 
added a saturated aqueous solution of sodium bicarbonate (10 mL) and the organic 
and the aqueous layers were separated. The latter was extracted with CH2Cl2 (3 x 
20 mL). The combined organic layers were dried (Na2SO4), filtered and the filtrate 
was concentrated in vacuo. The residue was purified by chromatography (silica gel, n-
heptane / EtOAc) to give product 6.  
 
Methyl-4-hydroxy-2,6-dimethylbiphenyl-3-carboxylate(6a): Starting with 1,3-
bis(silyl enol ether) 5a (600 mg, 2.30 mmol), 3-phenyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4a (571 mg, 2.30 mmol) and 
TiCl4 (0.25 mL, 2.30 mmol), 6a was obtained as a light yellow solid 
(360 mg, 61%), mp = 80-82 °C. 1H-NMR (300 MHz, CDCl3):  = 
1.93 (s, 3H, CH3), 2.17 (s, 3H, CH3), 3.91 (s, 3H, OCH3), 6.76 (s, 
1H, HAr), 7.05 (d (br.), 2H, 3J = 7.0 Hz, HAr), 7.31-7.41 (m, 3H, HAr), 11.01 (s, 1H, 
OH); 13C-NMR (75 MHz, CDCl3):  = 20.8, 21.9 (CH3), 52.1 (OCH3), 110.8 (CAr), 
116.2 (CHAr), 126.8 (CHPh), 128.6 (2CHPh), 129.7 (2CHPh), 135.2, 138.5, 140.9, 
144.0, 161.1 (CAr), 172.3 (C=O); IR (KBr, cm–1): v~  =  3060, 3004, 2953, 2852 (w), 
1655, 1597 (m), 1441 (s), 1356 (m), 1318, 1228 (s), 1092 (m), 990 (w), 881, 810 (m), 
701 (s); MS (EI, 70 eV): m/z (%) = 256 (M+, 77), 225 (61), 224 (100), 196 (40), 181 
(10), 167 (18), 165 (14), 153 (17), 152 (22); HRMS (EI): calcd. for C16H16O3 [M]+: 





Ethyl 4-hydroxy-2,6-dimethylbiphenyl-3-carboxylate (6b): Starting with 1,3-
bis(silyl enol ether) 5b (600 mg, 2.18 mmol), 3-phenyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4a (542 mg, 2.18 mmol) and 
TiCl4 (0.24 mL, 2.18  mmol), 6b was obtained as a colorless solid 
(236 mg, 40%), mp = 78-79 °C. 1H-NMR (300 MHz, CDCl3):  = 
1.34 (t, 3H, 3J = 7.0 Hz, CH3), 1.90 (s, 3H, CH3), 2.16 (s, 3H, CH3), 4.36 (q, 2H, 3J = 
7.0 Hz, OCH2), 6.73 (s, 1H, HAr), 7.03 (d (br.), 2H, 3J = 6.9 Hz, HAr), 7.28-7.37 (m, 





(CH3), 61.5 (OCH2), 111.0 (CAr), 116.2 (CHAr), 126.8 (CHPh), 128.6 (2CHPh), 129.8 
(2CHPh), 135.1, 138.6, 140.9, 143.8, 161.1 (CAr), 171.8 (C=O); IR (KBr, cm–1): v~  =  
3057, 3005, 2983, 2873 (w), 1648 (s), 1597, 1462, 1371, 1315 (m), 1224, 1091 (s), 
1008, 857, 802 (m), 707 (s); MS (EI, 70 eV): m/z (%) = 270 (M+, 84), 225 (79), 224 
(100), 196 (43), 181 (12), 167 (20), 165 (18), 153 (21), 152 (24); HRMS (EI): calcd. 
for C17H18O3 [M]+: 270.12505; found: 270.12507. 
 
Benzyl 4-hydroxy-2,6-dimethylbiphenyl-3-carboxylate (6c):  Starting with 1,3-
bis(silyl enol ether) 5c (600 mg, 1.78 mmol), 3-phenyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4a (442 mg, 1.78 mmol) and 
TiCl4 (0.19 mL, 1.78 mmol), 6c was obtained as a light yellow solid 
(207 mg, 35%), mp = 59-60 °C. 1H-NMR (250 MHz, CDCl3):  = 
1.87 (s, 3H, CH3), 2.12 (s, 3H, CH3), 5.32 (s, 2H, OCH2), 6.71 (s, 1H, HAr), 6.98-7.34 
(m, 10H, 2Ph), 10.97 (s, 1H, OH); 13C-NMR (62 MHz, CDCl3):  = 21.2, 21.9 (CH3), 
67.3 (OCH2), 110.8 (CAr), 116.2 (CHAr), 126.8 (CHPh), 128.5 (2CHPh), 128.6 (3CHPh), 
128.7 (2CHPh), 129.8 (2CHPh), 135.2, 137.0, 138.7, 140.8, 144.1, 161.2 (CAr), 171.6 
(C=O); IR (KBr, cm–1): ~  = 3059, 2964, 1950, 1879, 1726 (w), 1649 (s), 1595, 1495, 
1449 (m), 1375, 1311, 1221 (s), 1153 (m), 1089 (s), 1026, 985, 934, 884, 802 (m), 
751, 694 (s), 639, 576 (m); MS (EI, 70 eV): m/z (%) = 332 (M+, 25), 314 (4), 225 
(11), 224 (55), 223 (5), 165 (5), 152 (6), 91 (100), 65 (5); HRMS (EI): calcd. for 





Methyl 4-hydroxy-2,5,6-trimethylbiphenyl-3-carboxylate (6d): Starting with 1,3-
bis(silyl enol ether) 5d (500 mg, 1.82 mmol), 3-phenyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4a (452 mg, 1.82 mmol) and TiCl4 
(0.20 mL, 1.82 mmol), 6d was obtained as a colorless solid (236 mg, 
48%), mp = 99-101 °C. 1H-NMR (300 MHz, CDCl3):  = 1.85 (s, 3H, 
CH3), 2.06 (s, 3H, CH3), 2.14 (s, 3H, CH3), 3.85 (s, 3H, OCH3), 6.98 
(d (br.), 2H, 3J = 6.9 Hz, HAr), 7.23-7.35 (m, 3H, HAr), 11.20 (s, 1H, OH); 13C-NMR 
(75 MHz, CDCl3):  = 12.0, 18.8, 20.9 (CH3), 52.0 (OCH3), 110.2 (CAr), 126.6 
(CHPh), 127.5 (CAr), 128.5 (2CHPh), 129.9 (2CHPh), 135.1, 136.9, 141.9, 142.2, 159.0 




m ~  = 3074, 3020, 2926, 2857 (w), 1652, 1600, 
1537, 1403 (m), 1326, 1223 (s), 1141, 1068, 983 (m), 911 (w), 806, 765 (m), 702 (s), 
 50
609, 556 (m); GC-MS (EI, 70 eV): m/z (%) = 271 (8), 270 (M+, 46), 239 (25), 238 
(100), 237 (27), 210 (31), 196 (11), 195 (55), 165 (30), 152 (15), 77 (5); HRMS (EI): 
calcd. for C17H18O3 [M]+: 270.12505; found: 270.12488. 
 
Methyl 5-ethyl-4-hydroxy-2,6-dimethylbiphenyl-3-carboxylate (6e): Starting with 
1,3-bis(silyl enol ether) 5e (600 mg, 2.07 mmol), 3-phenyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4a (514 mg, 2.07 mmol) and TiCl4 
(0.22 mL, 2.07 mmol), 6e was obtained as a colorless solid (312 mg, 
53%), mp = 125-126 °C. 1H-NMR (300 MHz, CDCl3): δ = 1.07 (t, 3H, 
3J = 7.4 Hz, CH3), 1.87 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.67 (q, 2H, 3J = 7.4 Hz, 
CH2), 3.86 (s, 3H, OCH3), 6.99 (d (br.), 2H, 3J = 6.8 Hz, HAr), 7.22-7.34 (m, 3H, HAr), 
11.18 (s, IH, OH); 13C-NMR (75 MHz, CDCl3): δ = 12.2, 16.9 (CH3), 18.8 (CH2), 
19.8 (CH3), 50.9 (OCH3), 109.4 (CAr), 125.5 (CHPh), 127.3 (CAr), 127.4 (2CHPh), 
128.8 (2CHPh), 134.0, 134.2, 140.4, 140.9, 157.8 (CAr), 171.8 (C=O); IR (KBr, cm–1): 
~  = 3072 (w), 2971, 2876, 1650, 1599 (m), 1493 (w), 1435, 1364, 1321 (m), 1221 (s), 
1142, 1067, 1001, 952 (m), 853 (w), 808, 705 (s), 650, 580 (m); GC-MS (EI, 70 eV): 
m/z (%) = 284 (M+, 73), 253 (30), 252 (100), 251 (69), 224 (96), 209 (43), 196 (10), 
195 (40), 178 (12), 166 (21), 165 (47), 152 (13); HRMS (EI): calcd. for C18H20O3 





Methyl 4-hydroxy-2,6-dimethyl-5-phenethylbiphenyl-3-carboxylate (6f): Starting 
with 1,3-bis(silyl enol ether) 5f (500 mg, 1.37 mmol), 3-phenyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4a (340 mg, 1.37 mmol) and 
TiCl4 (0.15 mL, 1.37 mmol), 6f was obtained as a colorless solid 
(187 mg, 38%), mp = 109-111 °C. 1H-NMR (300 MHz, CDCl3):  
= 1.64 (s, 3H, CH3), 1.94 (s, 3H, CH3), 2.63 (t, 2H, 3J = 5.0 Hz, CH2), 2.78 (t, 2H, 3J 
= 5.0 Hz, CH2), 3.78 (s, 3H, OCH3), 6.84 (d (br.), 2H, 3J  = 6.8 Hz, HAr), 7.03-7.23 
(m, 8H, HAr), 11.17 (s, 1H, OH); 13C-NMR (75 MHz, CDCl3):  = 19.3, 22.1 (CH3), 
30.3, 36.3 (CH2), 53.2 (OCH3), 111.7 (CAr), 127.0 (CHPh), 127.2 (CAr), 127.8 (CHPh), 
129.4 (2CHPh), 129.7 (2CHPh), 129.8 (2CHPh), 131.0 (2CHPh), 136.3, 136.8, 143.0, 
143.1, 143.7, 160.4 (CAr), 174.0 (C=O); IR (KBr, cm–1): ~  = 3081, 3025, 2950, 2865 
(w), 1650, 1596, 1494, 1438 (m), 1325, 1219 (s), 1163, 1082, 1033, 987, 912, 804 





(24), 237 (100), 166 (7), 165 (11); HRMS (EI): calcd. for C24H24O3 [M]+: 360.17200; 
found: 360.17109 
 
Methyl 4-hydroxy-2,6-dimethyl-5-pentylbiphenyl-3-carboxylate (6g): Starting 
with 1,3-bis(silyl enol ether) 5g (700 mg, 2.11 mmol), 3-phenyl-
4-(trimethylsilyloxy)pent-3-en-2-one 4a (524 mg, 2.11 mmol) 
and TiCl4 (0.23 mL, 2.11 mmol), 6g was obtained as a light 
yellow solid (345 mg, 50%), mp = 102-104 °C. 1H-NMR (300 
MHz, CDCl3): δ = 0.71 (t, 3H, 3J = 7.6 Hz, CH3), 1.09-1.31 (m, 
6H, 3CH2), 1.75 (s, 3H, CH3), 1.94 (s, 3H, CH3), 2.52 (t, 2H, 3J = 7.4 Hz, CH2), 3.75 
(s, 3H, OCH3), 6.89 (d (br.), 2H, 3J = 6.8 Hz, HAr), 7.13-7.24 (m, 3H, Ph), 11.05 (s, 
1H, OH); 13C-NMR (62 MHz, CDCl3): δ = 15.2, 19.3, 22.0 (CH3), 23.8, 27.8, 29.9, 
33.4 (CH2), 53.1 (OCH3), 111.6 (CAr), 127.7 (CHPh), 128.4 (CAr), 129.7 (2CHPh), 
131.0 (2CHPh), 136.2, 136.3, 142.8, 143.2, 160.2 (CAr), 174.0 (C=O); IR (KBr, cm–1): 
~  = 2953 (m), 2857, 1933 (w), 1702, 1655, 1595, 1438, 1377, 1326 (m), 1213 (s), 
1142, 1048, 1003 (m), 903 (w), 839 (s), 772 (m), 702 (s), 627, 579 (w); GC-MS (EI, 
70 eV): m/z (%) = 326 (M+, 76), 294 (33), 277 (63), 265 (25), 251 (22), 239 (19), 238 
(100), 237 (81), 210 (30), 195 (24), 166 (25), 165 (54), 152 (10); HRMS (EI): calcd. 






Methyl 5-hexyl-4-hydroxy-2,6-dimethylbiphenyl-3-carboxylate (6h): Starting with 
1,3-bis(silyl enol ether) 5h (500 mg, 1.45 mmol), 3-phenyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4a (360 mg, 1.45 mmol) and 
TiCl4 (0.16 mL, 1.45 mmol), 6h was obtained as a light 
yellowish solid (227 mg, 46%), mp = 105-107 °C. 1H-NMR (300 
MHz, CDCl3): δ = 0.71 (t, 3H, 3J = 7.1 Hz, CH3), 1.09-1.34 (m, 
8H, 4CH2), 1.75 (s, 3H, CH3), 1.94 (s, 3H, CH3), 2.52 (t, 2H, 3J = 7.2 Hz, CH2), 3.75 
(s, 3H, OCH3), 6.89 (d (br.), 2H, 3J = 6.8 Hz, HAr), 7.12-7.25 (m, 3H, Ph), 11.06 (s, 
1H, OH); 13C-NMR (62 MHz, CDCl3): δ = 15.3, 19.3, 22.0 (CH3), 23.8, 27.8, 30.2, 
30.9, 32.9 (CH2), 53.1 (OCH3), 111.5 (CAr), 127.7 (CHPh), 128.4 (CAr), 129.6 (2CHPh), 
131.0 (2CHPh), 136.2, 136.3, 142.7, 143.2, 160.2 (CAr), 174.0 (C=O); IR (KBr, cm–1): 
~  = 2955 (m), 2852 (w), 1652, 1597, 1537, 1405 (m), 1328, 1217 (s), 1141, 1065 (m), 





(%) = 340 (M+, 65), 308 (30), 293 (43), 291 (53), 279 (33), 265 (25), 251 (20), 239 
(20), 238 (100), 237 (76), 210 (26), 195 (21), 165 (43), 152 (9); HRMS (EI): calcd. 
for C22H28O3 [M]+: 340.20330; found: 340.20341. 
 
Methyl 5-(but-3-enyl)-4-hydroxy-2,6-dimethylbiphenyl-3-carboxylate (6i): 
Starting with 1,3-bis(silyl enol ether) 5i (600 mg, 1.90 mmol), 3-
phenyl-4-(trimethylsilyloxy)pent-3-en-2-one 4a (472 mg, 1.90 
mmol) and TiCl4 (0.20 mL, 1.90 mmol), 6i was obtained as a light 
yellowish solid (283 mg, 48%), mp = 112-114 °C. 1H-NMR (300 
MHz, CDCl3): δ = 1.76 (s, 3H, CH3), 1.95 (s, 3H, CH3), 2.07-2.13 (m, 2H, CH2), 2.63 
(t, 2H, 3J = 7.8 Hz, CH2), 3.78 (s, 3H, OCH3), 4.77-4.92 (m, 2H, =CH2), 5.69-5.83 (m, 
1H, =CH), 6.89 (d, 2H,  3J = 6.8 Hz, HAr), 7.11-7.25 (m, 3H, Ph), 11.09 (s, 1 H, OH); 
13C-NMR (62 MHz, CDCl3): δ = 19.4, 22.0 (CH3), 27.4, 34.2 (CH2), 53.2 (OCH3), 
111.6 (CAr), 115.6 (=CH2), 127.7 (CHPh), 128.6 (CAr), 129.7 (2CHPh), 131.0 (2CHPh), 
136.3, 136.7 (CAr), 139.9 (=CH), 142.9, 143.1, 160.2 (CAr), 174.0 (C=O); IR (KBr, 
cm–1): ~  = 3057, 2952 (w), 1708, 1651, 1597, 1493, 1404, 1325 (m), 1215 (s), 1142, 
1071, 1000, 908, 763, 763 (m), 701 (s), 609, 555 (m); GC-MS (EI, 70 eV): m/z (%) = 
310 (M+, 11), 270 (5), 269 (24), 238 (17), 237 (100), 166 (9), 165 (18), 152 (3); 





Methyl 5-chloro-4-hydroxy-2,6-dimethylbiphenyl-3-carboxylate (6j): Starting 
with 1,3-bis(silyl enol ether) 5j (600 mg, 2.03 mmol), 3-phenyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4a (504 mg, 2.03 mmol) and TiCl4 
(0.22 mL, 2.03 mmol), 6j was obtained as a colorless solid (218 mg, 
37%), mp = 98-99 °C. 1H-NMR (250 MHz, CDCl3):  = 2.07 (s, 3H, 
CH3), 2.14 (s, 3H, CH3), 3.97 (s, 3H, OCH3), 7.06 (d, 2H, 3J = 6.9 Hz, HAr), 7.32-7.43 
(m, 3H, HAr), 11.40 (s, 1H, OH); 13C-NMR (62 MHz, CDCl3):  = 19.4, 20.7 (CH3), 
52.5 (OCH3), 115.2 (CAr), 127.4 (CHPh), 128.7 (CAr), 129.6 (2CHPh), 131.0 (2CHPh), 
136.4, 136.9, 140.6, 141.4, 156.1 (CAr), 171.9 (C=O); IR (KBr, cm–1): ~  = 3023 (m), 
2958, 2851, 1731 (w), 1657 (s), 1595, 1493, 1437 (m), 1363 (s), 1285 (m), 1225 (s), 
1072,  995 (m), 910 (w), 804 (s), 736 (m), 702 (s), 602, 558 (m); GC-MS (EI, 70 eV): 






(9), 166 (7), 165 (17), 152 (13); HRMS (EI): calcd. for C16H15ClO3 [M]+: 290.07042; 
found: 290.07071. 
 
Methyl 4-hydroxy-2,4',6-trimethylbiphenyl-3-carboxylate (6k): Starting with 1,3-
bis(silyl enol ether) 5a (600 mg, 2.30 mmol), 3-p-tolyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4b (603 mg, 2.30 mmol) and TiCl4 
(0.25 mL, 2.30 mmol), 6k was obtained as white solid (335 mg, 54%), 
mp = 112-114 oC. 1H-NMR (300 MHz, CDCl3):  = 1.98 (s, 3H, CH3), 
2.21 (s, 3H, CH3), 2.42 (s, 3H, CH3), 3.96 (s, 3H, OCH3), 6.79 (s, 1H, HAr), 6.97 (d 
(br.), 2H, 3J = 8.1 Hz, HAr), 7.21 (d (br.), 2H, 3J = 8.1 Hz, HAr), 11.01 (s, 1H, OH); 
13C-NMR (75 MHz, CDCl3):  = 20.8, 21.2, 21.9 (CH3), 52.0 (OCH3), 110.7 (CAr), 
116.1 (CHAr), 129.2 (2CHAr), 129.5 (2CHAr), 135.1, 136.2, 137.7, 138.6, 144.2, 160.9 
(CAr), 172.2 (C=O); IR (KBr, cm–1): ~  = 3408, 2952, 1808 (w), 1708, 1664, 1605, 
1512, 1438, 1351, 1319 (m), 1222 (s), 1156 (s), 1090 (m), 994, 899, 805, 733, 654, 
564 (m); GC-MS (EI, 70 eV): m/z (%) = 270 (M+, 36), 239 (23), 238 (100), 210 (12), 






Ethyl 4-hydroxy-2,4',6-trimethylbiphenyl-3-carboxylate (6l): Starting with 1,3-
bis(silyl enol ether) 5b (600 mg, 2.18 mmol), 3-p-tolyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4b (572 mg, 2.18 mmol) and 
TiCl4 (0.24 mL, 2.18 mmol), 6l was obtained as a white solid (248 
mg, 40%), mp = 117-119 °C. 1H-NMR (300 MHz, CDCl3):  = 1.38 
(t, 3H, 3J = 7.1 Hz, CH3), 1.95 (s, 3H, CH3), 2.21 (s, 3H, CH3), 2.38 
(s, 3H, CH3), 4.40 (q, 2H, 3J = 7.1 Hz, OCH2), 6.76 (s, 1H, HAr), 6.95 (d (br.), 2H, 3J 
= 8.0 Hz, HAr), 7.18 (d (br.), 2H, 3J = 8.0 Hz, HAr), 11.07 (s, 1H, OH); 13C-NMR (75 
MHz, CDCl3):  = 14.2, 20.9, 21.2, 21.9 (CH3), 61.4 (OCH2), 111.0 (CAr), 116.2 
(CHAr), 129.2 (2CHAr), 129.6 (2CHAr), 135.1, 136.2, 137.9, 138.7, 144.0, 161.0 (CAr), 
171.8 (C=O); IR (KBr, cm–1): ~  = 3049, 2919, 2860 (w), 1645, 1595, 1514, 1463, 
1392 (m), 1314 (s), 1224 (m), 1103 (w), 1061, 994, 920 (m), 813 (s), 723, 653, 551 
(m); GC-MS (EI, 70 eV): m/z (%) = 284 (M+, 30), 239 (24), 238 (100), 210 (13), 195 






 Methyl 4-hydroxy-2,4',5,6-tetramethylbiphenyl-3-carboxylate carboxylate (6m): 
Starting with 1,3-bis(silyl enol ether), 5d (600 mg, 2.18 mmol), 3-p-
tolyl-4-(trimethylsilyloxy)pent-3-en-2-one 4b (572 mg, 2.18 mmol) 
and TiCl4 (0.24 mL, 2.18 mmol), 6m was obtained as a white solid 
(254 mg, 41%), mp = 143-145 °C. 1H-NMR (300 MHz, CDCl3):  = 
1.89 (s, 3H, CH3), 2.10 (s, 3H, CH3), 2.21 (s, 3H, CH3), 2.39 (s, 3H, CH3), 3.93 (s, 
3H, OCH3), 6.92 (d (br.), 2H, 3J = 7.9 Hz, HAr), 7.21 (d (br.), 2H, 3J = 7.9 Hz, HAr), 
11.28 (s, 1H, OH); 13C-NMR (75 MHz, CDCl3):  = 12.0, 18.8, 20.9, 21.2 (CH3), 52.0 
(OCH3), 110.2, 122.2 (CAr), 129.2 (2CHAr), 129.7 (2CHAr), 134.8, 135.2, 136.1, 
138.8, 142.4, 158.9 (CAr), 172.9 (C=O); IR (KBr, cm–1): ~  = 3012, 2953, 2864, 1711 
(w), 1651, 1597, 1514, 1404 (m), 1327 (s), 1294 (m), 1222 (s), 1141, 1060, 987, 919, 
857 (m), 804 (s), 736, 698, 551 (m); GC-MS (EI, 70 eV): m/z (%) = 284 (M+, 42), 253 
(23), 252 (100), 251 (16), 237 (15), 224 (22), 210 (9), 209 (43), 181 (13), 166 (13), 






Methyl 5-ethyl-4-hydroxy-2,4',6-trimethylbiphenyl-3-carboxylate (6n): Starting 
with 1,3-bis(silyl enol ether) 5e (600 mg, 2.07 mmol), 3-p-tolyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4b (543 mg, 2.07 mmol) and 
TiCl4 (0.22 mL, 2.07 mmol), 6n was obtained as a white solid (284 
mg, 46%), mp = 137-138 °C. 1H-NMR (300 MHz, CDCl3): δ = 0.96 
(t, 3H, 3J = 7.4 Hz, CH3), 1.77 (s, 3H, CH3), 1.95 (s, 3H, CH3), 2.22 (s, 3H, CH3), 2.56 
(q, 2H, 3J = 7.4 Hz, CH2), 3.75 (s, 3H, OCH3), 6.78 (d (br.), 2H, 3J = 7.8 Hz, HAr), 
7.03 (d (br.), 2H, 3J = 7.8 Hz, HAr), 11.05 (s, IH, OH); 13C-NMR (75 MHz, CDCl3): δ 
= 13.2, 17.9 (CH3), 19.8 (CH2), 20.8, 21.2 (CH3), 51.9 (OCH3), 110.4, 128.2 (CAr), 
129.1 (2CHAr), 129.7 (2CHAr), 135.0, 135.3, 136.0, 138.8, 141.6, 158.7 (CAr), 172.8 
(C=O); IR (KBr, cm–1): ~  = 3009 (w), 2953 (m), 2873 (w), 1650, 1597, 1514, 1434, 
1358, 1290 (m), 1221 (s), 1141, 1066, 987 (m), 855 (w), 807 (s), 695 (m), 590 (w), 
529 (m); GC-MS (EI, 70 eV): m/z (%) = 298 (M+, 87), 267 (30), 266 (100), 265 (55), 
251 (85), 238 (80), 223 (44), 209 (42), 195 (11), 179 (22), 165 (34); HRMS (EI): 






Methyl 4-hydroxy-2,4',6-trimethyl-5-phenethyl-biphenyl-3-carboxylate (6o): 
Starting with 1,3-bis(silyl enol ether) 5f (600 mg, 1.64 mmol), 3-
p-tolyl-4-(trimethylsilyloxy)pent-3-en-2-one 4b (430 mg, 1.64 
mmol) and TiCl4 (0.18 mL, 1.64 mmol), 6o was obtained as a 
white solid (221 mg, 36%), mp = 122-124 °C. 1H-NMR (300 
MHz, CDCl3):  = 1.72 (s, 3H, CH3), 1.96 (s, 3H, CH3), 2.23 (s, 
3H, CH3), 2.66 (t, 2H, 3J = 5.0 Hz, CH2), 2.79 (t, 2H, 3J = 5.0 Hz, CH2), 3.76 (s, 3H, 
OCH3), 6.79 (d (br.), 2H, 3J = 7.9 Hz, HAr), 7.04 (d (br.), 2H, 3J = 7.9 Hz, HAr), 11.16 
(s, 1H, OH); 13C-NMR (75 MHz, CDCl3):  = 19.3, 22.1, 22.4, (CH3), 30.4, 36.3 
(CH2), 53.2 (OCH3), 111.6 (CAr), 127.0 (CHAr), 127.1 (CAr), 129.4 (2CHAr), 129.6 
(2CHAr), 129.7 (2CHAr), 130.4 (2CHAr), 136.2, 137.0, 137.3, 140.0, 143.2, 143.8, 
160.2 (CAr), 174.0 (C=O); IR (KBr, cm–1): ~  = 3025, 2947, 2862, 1699 (w), 1650, 
1600, 1513, 1440, 1406 (m), 1325, 1225 (s), 1145, 1085, 990, 920, 872 (m), 807 (s), 
753, 698 (m), 632 (w), 549 (m); MS (EI, 70 eV): m/z (%) = 374 (M+, 29), 342 (5), 283 
(28), 252 (22), 251 (100), 180 (5), 165 (9), 91 (4); HRMS (EI): calcd. for C25H26O3 





Methyl 5-hexyl-4-hydroxy-2,4',6-trimethylbiphenyl-3-carboxylate (6p): Starting 
with 1,3-bis(silyl enol ether) 5h (600 mg, 1.74 mmol), 3-p-tolyl-4-
(trimethylsilyloxy)pent-3-en-2-one 4b (457 mg, 1.74 mmol) and 
TiCl4 (0.19 mL, 1.74 mmol), 6p was obtained as white solid (259 
mg, 42%), mp = 105-107 °C. 1H-NMR (300 MHz, CDCl3): δ = 
0.71 (t, 3H, 3J = 7.2 Hz, CH3), 1.09-1.34 (m, 8H, 4CH2), 1.76 (s, 
3H, CH3), 1.95 (s, 3H, CH3), 2.23 (s, 3H, CH3), 2.51 (t, 2H, 3J = 7.1 Hz, CH2), 3.75 
(s, 3H, OCH3), 6.77 (d (br.), 2H, 3J = 7.8 Hz, HAr), 7.03 (d (br.), 2H, 3J = 7.8 Hz, 
HAr), 11.03 (s, IH, OH); 13C-NMR (75 MHz, CDCl3): δ = 15.3, 19.4, 22.0, 22.5 
(CH3), 23.8, 27.9, 30.2, 30.9, 32.9 (CH2), 51.1 (OCH3), 111.5, 128.3 (CAr), 130.6 
(2CHAr), 132.1 (2CHAr), 136.1, 136.5, 138.3, 140.1, 143.0, 160.0 (CAr), 174.0 (C=O); 
IR (KBr, cm–1): ~  = 2953, 2855, 1933 (w), 1702, 1655, 1593 (m), 1513 (w), 1437, 
1378, 1325 (m), 1216 ( s), 1141 (m), 1051, 987 (m), 902 (w), 841 (s), 765, 696 (m), 
628, 557 (w); GC-MS (EI, 70 eV): m/z (%) = 354 (M+, 45), 322 (19), 307 (53), 305 
(37), 293 (24), 279 (21), 253 (26), 252 (100), 251 (61), 224 (19), 209 (31), 207 (56), 




4.21895; found: 354.21973. 
 56
 Methyl 4'-butyl-4-hydroxy-2,6-dimethylbiphenyl-3-carboxylate (6q): Starting 
with 1,3-bis(silyl enol ether) 5a (600 mg, 2.30 mmol), 3-(4-
butylphenyl)-4-(trimethylsilyloxy)pent-3-en-2-one 4c (700 mg, 2.30 
mmol) and TiCl4 (0.25 mL, 2.30 mmol), 6q was obtained as a colorless 
solid (373 mg, 52%), mp = 66-68 °C. 1H-NMR (300 MHz, CDCl3):  = 
0.87 (t, 3H, 3J = 7.3 Hz, CH3), 1.32 (sextet, 2H, 3J = 7.3 Hz, CH2), 
1.57 (quintet, 2H, 3J = 7.7 Hz, CH2), 1.88 (s, 3H, CH3), 2.11 (s, 3H, CH3), 2.58 (t, 2H, 
3J = 7.6 Hz, CH2), 3.86 (s, 3H, OCH3), 6.69 (s, 1H, HAr), 6.88 (d, 2H, 3J = 8.1 Hz, 
HAr), 7.14 (d, 2H, 3J = 8.1 Hz, HAr), 10.91 (s, 1H, OH); 13C-NMR (75 MHz, CDCl3): 
 = 14.0, 20.8, 21.9 (CH3), 22.4, 33.5, 35.4 (CH2), 52.0 (OCH3), 110.7 (CAr), 116.1 
(CHAr), 128.5 (2CHAr), 129.5 (2CHAr), 135.2, 137.9, 138.7, 141.3, 144.3, 160.9 (CAr), 
172.3 (C=O); IR (KBr, cm–1): ~  = 2953, 2856, 1730 (w), 1657 (s), 1599, 1512, 1437, 
1376, 1318 (m), 1220 (s), 1113, 1061, 993, 858, 803, 736 (m), 653 (w), 575 (m); GC-
MS (EI, 70 eV): m/z (%) = 312 (M+, 24), 281 (25), 280 (100), 237 (12), 209 (11), 166 






Ethyl 4'-butyl-4-hydroxy-2,6-dimethylbiphenyl-3-carboxylate (6r): Starting with 
1,3-bis(silyl enol ether) 5b (600 mg, 2.18 mmol), 3-(4-butylphenyl)-4-
(trimethylsilyloxy)pent-3-en-2-one 4c (664 mg, 2.18 mmol) and TiCl4 
(0.24 mL, 2.18 mmol), 6r was obtained as a colorless solid (320 mg, 
45%), mp = 73-75 oC. 1H-NMR (300 MHz, CDCl3):  = 0.88-0.98 (m, 
6H, 2CH3), 1.34 (sextet, 2H, 3J = 7.2 Hz, CH2), 1.58 (quintet, 2H, 3J = 
7.3 Hz, CH2), 1.89 (s, 3H, CH3), 2.15 (s, 3H, CH3), 2.59 (t, 2H, 3J = 7.6 Hz, CH2), 
4.41 (q, 2H, 3J = 7.2 Hz, OCH2), 6.71 (s, 1H, HAr), 6.90 (d, 2H, 3J = 8.0 Hz, HAr), 
7.14 (d, 2H, 3J = 8.0 Hz, HAr), 11.01 (s, 1H, OH); 13C-NMR (75 MHz, CDCl3):  = 
13.9, 14.1, 20.9, 21.9 (CH3), 22.4, 33.5, 35.3 (CH2), 61.4 (OCH2), 110.9 (CAr), 116.0 
(CHAr), 128.4 (2CHAr), 129.5 (2CHAr), 135.1, 138.7, 141.2, 142.1, 144.1, 160.9 (CAr), 
171.8 (C=O); IR (KBr, cm–1): ~  = 2956, 2858, 1809 (w), 1708 (m), 1654 (s), 1574 
(m), 1510 (w), 1462, 1395 (m), 1314, 1221 (s), 1178, 1091, 1012 (m), 931 (w), 859, 





(100), 252 (4), 237 (10), 209 (10), 166 (4), 165 (9), 152 (3); HRMS (EI): calcd. for 
C21H26O3 [M]+: 326.18765; found: 326.18752. 
 
Benzyl 4'-butyl-4-hydroxy-2,6-dimethylbiphenyl-3-carboxylate (6s): Starting with 
1,3-bis(silyl enol ether) 5c (500 mg, 1.45 mmol), 3-(4-butylphenyl)-
4-(trimethylsilyloxy)pent-3-en-2-one 4c (442 mg, 1.45 mmol) and 
TiCl4 (0.16 mL, 1.45 mmol), 6s was obtained as a yellowish solid 
(215 mg, 38%), mp = 64-66 °C. 1H-NMR (300 MHz, CDCl3):  = 
0.89 (t, 3H, 3J = 7.3 Hz, CH3), 1.31 (sextet, 2H, 3J = 7.3 Hz, CH2), 
1.57 (quintet, 2H, 3J = 7.8 Hz, CH2), 1.89 (s, 3H, CH3), 2.12 (s, 3H, CH3), 2.57 (t, 2H, 
3J = 7.5 Hz, CH2), 5.33 (s, 2H, OCH2), 6.70 (s, 1H, HAr), 6.91-7.33 (m, 9H, HAr), 
10.93 (s, 1H, OH); 13C-NMR (75 MHz, CDCl3):  = 13.9, 21.2, 21.9 (CH3), 22.4, 
33.5, 35.3 (CH2), 67.3 (OCH2), 110.6 (CAr), 116.1 (CHAr), 128.4 (2CHAr), 128.5 
(CHAr), 128.6 (2CHAr), 128.7 (2CHAr), 129.5 (2CHAr), 135.2, 137.8, 138.8, 141.3, 
142.1, 144.4, 161.0 (CAr), 171.6 (C=O); IR (KBr, cm–1): ~  = 3032, 2955, 2857, 1760 
(w), 1709 (m), 1655 (s), 1573 (m), 1498 (w), 1416, 1344,1289 (m), 1216, 1156 (s), 
1088, 1028, 947, 835, 737, 653, 570 (m); GC-MS (EI, 70 eV): m/z (%) = 388 (M+, 
54), 346 (25), 282 (41), 281 (28), 280 (100), 254 (18), 237 (13), 208 (68), 165 (16), 





Methyl 4'-butyl-4-hydroxy-2,5,6-trimethylbiphenyl-3-carboxylate (6t): Starting 
with 1,3-bis(silyl enol ether) 5d (500 mg, 1.82 mmol), 3-(4-
butylphenyl)-4-(trimethylsilyloxy)pent-3-en-2-one 4c (554 mg, 1.82 
mmol) and TiCl4 (0.20 mL, 1.82 mmol), 6t was obtained as a colorless 
solid (344 mg, 58%), mp = 68-70 °C. 1H-NMR (300 MHz, CDCl3):  = 
0.88 (t, 3H, 3J = 7.5 Hz, CH3), 1.32 (sextet, 2H, 3J = 7.4 Hz, CH2), 1.58 
(quintet, 2H, 3J = 7.8 Hz, CH2), 1.84 (s, 3H, CH3), 2.06 (s, 3H, CH3), 2.13 (s, 3H, 
CH3), 2.58 (t, 2H, 3J = 7.6 Hz, CH2), 3.85 (s, 2H, OCH3), 6.87 (d, 2H, 3J = 8.2 Hz, 
HAr), 7.13 (d, 2H, 3J = 8.2 Hz, HAr), 11.21 (s, 1H, OH); 13C-NMR (75 MHz, CDCl3):  
= 12.0, 13.9, 18.7, 20.8 (CH3), 22.4, 33.6, 35.3 (CH2), 52.0 (OCH3), 110.2, 122.1 
(CAr), 128.4 (2CHAr), 129.6 (2CHAr), 134.9, 135.2, 138.9, 141.1, 142.2, 159.8 (CAr), 
172.9 (C=O); IR (KBr, cm–1): ~  = 3038 (w), 2955 (m), 2860, 1689 (w), 1649, 1597, 





708, 653, 594, 547 (m); GC-MS (EI, 70 eV): m/z (%) = 326 (M+, 31), 295 (25), 294 
(100), 293 (8), 266 (6), 251 (21), 237 (14), 223 (10), 209 (10), 179 (7), 165 (13), 152 
(2); HRMS (EI): calcd. for C21H26O3 [M]+: 326.18765; found: 326.18774. 
 
Methyl 4'-butyl-5-ethyl-4-hydroxy-2,6-dimethyl-biphenyl-3-carboxylate (6u): 
Starting with 1,3-bis(silyl enol ether) 5e (600 mg, 2.07 mmol), 3-(4-
butylphenyl)-4-(trimethylsilyloxy)pent-3-en-2-one 4c (630 mg, 2.07 
mmol) and TiCl4 (0.22 mL, 2.07 mmol), 6u was obtained as a 
colorless solid (387 mg, 55%), mp = 81-83 °C. 1H-NMR (300 MHz, 
CDCl3):  = 0.88 (t, 3H, 3J = 7.3 Hz, CH3), 1.05 (t, 3H, 3J = 7.5 Hz, 
CH3), 1.31 (sextet, 2H, 3J = 7.4 Hz, CH2), 1.58 (quintet, 2H, 3J = 7.8 Hz, CH2), 1.87 
(s, 3H, CH3), 2.05 (s, 3H, CH3), 2.58 (t, 2H, 3J = 7.6 Hz, CH2), 2.66 (q, 2H, 3J = 7.5 
Hz, CH2), 3.85 (s, 1H, OCH3), 6.88 (d, 2H, 3J = 8.2 Hz, HAr), 7.12 (d, 2H, 3J = 8.2 Hz, 
HAr), 11.15 (s, 1H, OH); 13C-NMR (75 MHz, CDCl3):  = 13.2, 13.9, 18.0 (CH3), 19.8 
(CH2), 20.9 (CH3), 22.4, 33.5, 35.4 (CH2), 51.9 (OCH3), 110.4, 128.2 (CAr), 128.4 
(2CHAr), 129.6 (2CHAr), 135.1, 135.4, 139.0, 141.0, 141.7, 158.7 (CAr), 172.8 (C=O); 
IR (KBr, cm–1): ~  = 2955 (m), 2871, 1730 (w), 1653 (s), 1593 (m), 1512 (w), 1438, 
1376, 1320 (m), 1212 (s), 1141, 1065, 987, 808, 756, 705, 649, 578 (m); GC-MS (EI, 
70 eV): m/z (%) = 340 (M+, 54), 309 (30), 308 (74), 307 (17), 281 (10), 280 (40), 265 
(28), 252 (17), 251 (100), 237 (15), 179 (16), 165 (16); HRMS (EI): calcd. for 






(6v): Starting with 1,3-bis(silyl enol ether) 5f (500 mg, 1.37 mmol), 
3-(4-butylphenyl)-4-(trimethylsilyloxy)pent-3-en-2-one 4c (417 
mg, 1.37 mmol) and TiCl4 (0.15 mL, 1.37 mmol), 6v was obtained 
as a colorless solid (211 mg, 37%), mp = 69-71 °C. 1H-NMR (300 
MHz, CDCl3): δ = 0.87 (t, 3H, 3J = 7.2 Hz, CH3), 1.32 (sextet, 2H, 
3J = 7.4 Hz, CH2), 1.58 (quintet, 2H, 3J = 7.8. Hz, CH2), 1.78 (s, 3H, CH3), 2.07 (s, 
3H, CH3), 2.58 (t, 2H, 3J = 7.5 Hz, CH2), 2.74 (t, 2H, 3J = 4.8 Hz, CH2), 2.92 (t, 2H, 
3J = 4.8 Hz, CH2), 3.87 (s, 3H, OCH3), 6.86 (d, 2H, 3J = 7.9 Hz, HAr), 7.11-7.23 (m, 
7H, HAr), 11.24 (s, 1H, OH); 13C-NMR (75 MHz, CDCl3): δ = 14.0, 18.1, 20.9 (CH3), 





(CAr), 128.2 (2CHAr), 128.4 (2CHAr), 128.7 (2CHAr), 129.6 (2CHAr), 135.1, 135.8, 
138.9, 141.1, 142.0, 142.6, 159.0 (CAr), 172.8 (C=O); IR (KBr, c –1): m ~  = 3024 (w), 
2951 (m), 2859 (w), 1707, 1650, 1599, 1512, 1452, 1405, 1354,1293 (m), 1220 (s), 
1160, 1083, 1029, 949, 870, 804, 743 (m), 696 (s), 614, 567 (m); EI-MS (EI, 70 eV): 
m/z (%) = 416 (M+, 24), 385 (16), 325 (42), 283 (28), 252 (35), 251 (100), 237 (10), 
180 (19), 165 (11), 152 (12), 91 (8); HRMS (EI): calcd. for C28H33O3 [M+H]+: 
417.24242; found: 417.24261. 
 
Methyl 4'-butyl-5-hexyl-4-hydroxy-2,6-dimethyl-biphenyl-3-carboxylate (6w): 
Starting with 1,3-bis(silyl enol ether) 5g (600 mg, 1.74 mmol), 
3-(4-butylphenyl)-4-(trimethylsilyloxy)pent-3-en-2-one 4c (530 
mg, 1.74 mmol) and TiCl4 (0.19 mL, 1.74 mmol), 6z was 
obtained as a yellowish solid (331 mg, 48%), mp = 84-85 °C. 
1H-NMR (300 MHz, CDCl3): δ = 0.71 (t, 3H, 3J = 7.2 Hz, CH3), 
0.78 (t, 3 H, 3J = 7.3 Hz, CH3), 1.09-1.59 (m, 12 H, 6CH2), 1.76 (s, 3 H, CH3), 1.95 (s, 
3 H, CH3), 2.47-2.52 (m, 4 H, 2CH2),  3.75 (s, 3H, OCH3), 6.78 (d, 2H, 3J = 7.9 Hz, 
HAr), 7.02 (d, 2 H, 3J = 7.9 Hz, HAr), 11.04 (s, 1 H, OH); 13C-NMR (75 MHz, CDCl3): 
δ = 15.2, 15.3, 19.4, 22.1 (CH3), 23.6, 23.8, 27.9, 30.2, 30.9, 32.9, 34.7, 36.5 (CH2),  
53.0 (OCH3), 111.5, 128.3 (CAr), 129.6 (2CHAr),  130.8 (2CHAr), 135.2, 136.3, 140.3, 
142.2, 143.0, 160.0 (CAr), 174.0 (C=O); IR (KBr, cm–1): ~  = 2953, 2855 (m), 1933 
(w), 1703 (m), 1654 (s), 1593 (m), 1512 (w), 1438, 1377, 1325 (m), 1213 (s), 1141, 
1057, 987 (m), 901 (w), 840, 752, 696, 651, 578 (m) cm-1MS (EI, 70 eV): m/z (%) = 
396 (M+, 42), 365 (25), 335 (35), 294 (100), 293 (54), 251 (18), 237 (29), 209 (19), 





 Methyl 4'-butyl-4-hydroxy-2,6-dimethyl-5-nonyl-biphenyl-3-carboxylate (6x): 
Starting with 1,3-bis(silyl enol ether) 5k (600 mg, 1.55 mmol), 3-(4-
butylphenyl)-4-(trimethylsilyloxy)pent-3-en-2-one 4c (472 mg, 1.55 
mmol) and TiCl4 (0.17 mL, 1.55 mmol), 6x was obtained as a 
yellowish solid (285 mg, 42%), mp = 66-68 °C. 1H-NMR (300 MHz, 
CDCl3): δ = 0.69 (t, 3H, 3J = 6.7 Hz, CH3), 0.78 (t, 3H, 3J = 7.2 Hz, 
CH3), 1.09-1.58 (m, 18H, 9CH2), 1.76 (s, 3H, CH3), 1.95 (s, 3H, CH3), 2.45-2.53 (m, 





Hz, HAr), 11.03 (s, 1H, OH); 13C-NMR (75 MHz, CDCl3): δ = 15.2, 15.3, 19.4, 22.1 
(CH3), 22.8, 23.6, 23.7, 27.8, 30.2, 30.5, 30.7, 30.8, 31.1, 34.8, 36.6 (CH2), 53.1 
(OCH3), 111.5, 128.2 (CAr), 129.6 (2CHAr), 130.8 (2CHAr), 136.2, 136.5, 140.2, 
142.2, 143.0, 160.0 (CAr), 174.0 (C=O); IR (KBr, cm–1): ~  = 2953, 2853 (m), 1731 
(w), 1654 (s), 1593 (m), 1512 (w), 1438 (m), 1325, 1212 (s), 1140, 1058, 987 (m), 
887 (w), 807, 752, 651, 578 (m); GC-MS (EI, 70 eV): m/z (%) = 438 (M+, 38), 406 
(22), 391 (30), 389 (32), 349 (56), 335 (51), 295 (20), 294 (100), 293 (50), 251 (14), 
237 (22), 209 (15), 165 (15); HRMS (EI): calcd for C29H42O3 [M]+: 438.64583; 
found: 438.64927. 
 
Methyl 5-allyl-4'-butyl-4-hydroxy-2,6-dimethyl-biphenyl-3-carboxylate (6y): 
Starting with 1,3-bis(silyl enol ether) 5l (600 mg, 1.99 mmol), 3-(4-
butylphenyl)-4-(trimethylsilyloxy)pent-3-en-2-one 4c (606 mg, 
1.99 mmol) and TiCl4 (0.21 mL, 1.99 mmol), 6y was obtained as a 
yellowish solid (386 mg, 55%), mp = 74-76 °C. 1H-NMR (300 
MHz, CDCl3): δ = 0.78 (t, 3H, 3J = 7.2 Hz, CH3), 1.18 (sextet, 2H, 
3J = 7.3 Hz, CH2), 1.45 (quintet, 2H, 3J = 7.6 Hz, CH2), 1.75 (s, 3H, 
CH3), 1.95 (s, 3H, CH3), 2.47 (t, 2H, 3J = 7.4 Hz, CH2), 3.32 (d, 2H, 3J = 5.7 Hz, 
CH2), 3.75 (s, 3H, OCH3), 4.76-4.98 (m, 2H, =CH2), 5.72-5.85 (m, 1H, =CH), 6.78 (d, 
2H, 3J = 8.1 Hz, HAr), 7.03 (d, 2H, 3J = 8.1 Hz, HAr), 11.09 (s, 1H, OH); 13C-NMR (75 
MHz, CDCl3): δ = 15.1, 19.4, 22.1 (CH3), 23.5, 30.8, 34.7, 36.5 (CH2), 53.2 (OCH3), 
111.7 (CAr), 115.7 (=CH2), 124.8 (CAr), 129.6 (2CHAr), 130.8 (2CHAr), 135.2, 136.4 
(CAr), 137.0 (=CH), 140.0, 142.3, 143.8, 159.9 (CAr), 173.9 (C=O); IR (KBr, cm–1): ~  
= 2955, 2926 (m), 2856 (w), 1656, 1595 (m), 1512 (w), 1438, 1325, 1287 (m), 1219 
(s), 1139, 1059, 993, 911, 833, 750, 654, 565 (m); GC-MS (EI, 70 eV): m/z (%) = 353 
(19), 352 (M+, 88), 320 (88), 305 (65), 292 (100), 263 (48), 249 (61), 235 (35), 203 
(32), 179 (25), 165 (10), 152 (11), 129 (31); HRMS (EI): calcd. for C23H28O3 [M]+: 










(6z): Starting with 1,3-bis(silyl enol ether) 5i (500 mg, 1.58 
mmol), 3-(4-butylphenyl)-4-(trimethylsilyloxy)pent-3-en-2-one 
4c (481 mg, 1.58 mmol) and TiCl4 (0.17 mL, 1.58 mmol), 6z was 
obtained as a  yellowish solid (306 mg, 53%), mp = 76-78 °C. 1H-
NMR (300 MHz, CDCl3): δ = 0.79 (t, 3H, 3J = 7.2 Hz, CH3), 1.20 
(sextet, 2H, 3J = 7.3 Hz, CH2), 1.44 (quintet, 2H, 3J = 7.6 Hz, 
CH2), 1.76 (s, 3H, CH3), 1.95 (s, 3H, CH3), 2.10-2.13 (m, 2H, CH2), 2.46 (t, 2H, 3J = 
7.4 Hz, CH2), 2.62 (t, 2H, 3J = 7.6 Hz, CH2), 3.75 (s, 3H, OCH3), 4.77-4.92 (m, 2H, 
=CH2), 5.69-5.83 (m, 1H, =CH), 6.78 (d, 2H, 3J = 8.0 Hz, HAr), 7.02 (d, 2H, 3J = 8.0 
Hz, HAr), 11.07 (s, 1H, OH); 13C-NMR (75 MHz, CDCl3): δ = 13.9, 18.3, 20.9 (CH3), 
22.4, 26.2, 33.0, 33.6, 35.3 (CH2), 52.0 (OCH3), 110.4 (CAr), 114.4 (=CH2), 126.0 
(CAr), 128.4 (2CHAr), 129.6 (2CHAr), 135.1, 135.7 (CAr), 138.8 (=CH), 139.0, 141.1, 
142.1, 158.9 (CAr), 172.8 (C=O); IR (KBr, cm–1): ~  = 2954 (m), 2858, 2667, 1786 
(w), 1710, 1655, 1606 (m), 1511 (w), 1438, 1377, 1324, 1286 (m), 1216 (s), 1157, 
1058, 991, 906,  807 (m), 751, 700 (s), 634 (w), 576 (m); GC-MS (EI, 70 eV): m/z 
(%) = 367 (33), 366 (M+, 100), 335 (25), 333 (12), 305 (9), 293 (24), 277 (11), 249 
(11), 235 (29), 203 (10), 179 (9), 165 (9), 152 (6), 115 (9); HRMS (EI): calcd. for 















General procedure for syntheses of 3,4-dibromo-5-arylpyrazoles: To a 1,4-
dioxane solution (4 mL) of 8a,b (0.5 mmol) was added Pd(PPh3)4 (3-10 mol %) at 20 
C under argon atmosphere. After stirring for 30 min, the arylboronic acid (1.0-1.2 
equiv. per bromine atom of the substrate), K3PO4 (1.5 equiv. per bromine atom of the 
substrate) and water (1.0 mL) were added. The mixture was heated for 12 h at 100 °C. 
After cooling to 20 C, the mixture was diluted with H2O, extracted with CH2Cl2 (3 x 
25 mL), dried (Na2SO4), and filtered. The solvent of the filtrate was concentrated in 
vacuo and the residue was purified by column chromatography (heptanes/EtOAc).  
 
3,4-Dibromo-5-(4-methoxyphenyl)-1-vinyl-1H-pyrazole (10a): Following the 
General procedure compound 10a was prepared from 8b 
(165 mg, 0.50 mmol), Pd(PPh3)4 (18 mg, 3 mol%), 1,4-
dioxane/H2O (4:1, 5 mL), K3PO4 (159 mg, 0.75 mmol) and 4-
methoxyphenylboronic acid (76 mg, 0.50 mmol) as a white 
solid (117 mg, 66%), m.p 145-147°C. 1H NMR (300 MHz, CDCl3): δ  = 3.80 (s, 3H, 
OCH3), 4.77 (d, 1H, J = 8.7 Hz, vinyl), 5.72 (d, 1H, J = 15.2 Hz, vinyl), 6.7 (dd, 1H, J 
= 15.2, 8.7 Hz vinyl CH), 6.95 (d, 2H, J = 8.8 Hz, ArH), 7.25 (d, 2H, J = 8.8 Hz, 
ArH).  13C NMR (75.5 MHz, CDCl3) : δ = 55.4 (OCH3), 98.2 (C), 102.7 (CH2), 114.3 
(CH), 119.0 (C), 129.7 (CH), 130.5 (C), 131.5 (CH), 142.4, 160.7 (C). IR (KBr): v = 
3002, 2936, 2835, 1730 (w), 1641 (m), 1574 (w), 1488 (s), 1432 (m), 1392 (w), 1355 
(m), 1332 (s), 1290 (m), 1249 (s), 1196 (w), 1174 (s), 1110 (m), 1030 (s), 984 (s), 888 
(m), 833 (s), 801 (m), 725 (w), 602 (m), 551 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 
358 ([M, 79Br, 81Br]+, 100), 356 ([M, 79Br, 79Br]+, 70) 343 (13), 327 (22), 277 (39), 
246 (22), 198 (23). HRMS (EI, 70 eV): calcd for C12H10N2Br2O [M, 79Br, 79Br]+: 






3,4-Dibromo-5-(2,6-dimethoxyphenyl)-1H-pyrazole (10b): Following the General 
procedure compound 10b was prepared from 8b (165 mg, 0.50 
mmol), Pd(PPh3)4 (18 mg, 3 mol%), 1,4-dioxane/H2O (4:1, 5 mL), 
K3PO4 (159 mg, 0.75 mmol) and 2,6-dimethoxyphenylboronic 
acid (91 mg, 0.50 mmol) as a  colourless oil (136 mg, 71%). 1H 
NMR (300 MHz, CDCl3): δ = 3.69 (s, 6H, 2OCH3), 4.65 (d, 1H, J = 8.6 Hz, vinyl), 








2H, J = 8.8 Hz, ArH), 7.33-7.39 (m, 1H, ArH). 13C NMR (75.5 MHz, CDCl3): δ = 
55.9 (2OCH3), 100.0 (C), 101.2 (CH2), 103.9 (CH), 104.3, 130.0 (C), 130.2, 132.5 
(CH), 137.0, 158.8 (C). IR (KBr): v = 3093, 2928, 2838, 1726 (w), 1643 (m), 1537 
(w), 1474 (s), 1431 (m), 1389 (w), 1356 (m), 1332 (s), 1297 (w), 1253 (s), 1187, 1173 
(w), 1253 (s), 1150 (w), 1107 (s), 1030 (w), 985 (s), 886 (w), 763 (m), 588 (w) cm-1. 
GC-MS (EI, 70 eV): m/z (%) = 390 ([M, 81Br, 81Br]+, 40), 388 ([M, 79Br, 81Br]+, 77), 
386 ([M, 79Br, 79Br]+, 39), 357 (100), 276 (26), 265 (13), 228 (42). HRMS (ESI+): 
calcd for C13H13 N2Br2O [M+1, 79Br, 81Br]+: 388.9918; found 388.9326, calcd for 
C13H13N2Br2O [M+1, 79Br, 79Br]+ : 386.9338; found 386.9344. 
 
4-Bromo-3,5-bis(4-methoxyphenyl)-1-vinyl-1H-pyrazole (11a): Following the 
General procedure compound 11a was prepared from 
8b (165 mg, 0.50 mmol), Pd(PPh3)4 (29 mg, 5 mol%), 
1,4-dioxane/H2O (4:1, 5 mL), K3PO4 (318 mg, 1.5 
mmol) and 4-methoxyphenylboronic acid (152 mg, 1.0 
mmol) as a  white crystalline solid, m.p 140-142°C. (77 mg, 40%).1H NMR (300 
MHz, CDCl3):  δ = 3.79 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 4.75 (d, 1H, J = 8.5 Hz, 
vinyl), 5.75 (d, 1H, J = 15.4 Hz, vinyl), 6.78 (dd, 1H, J = 8.8, 15.3 Hz,  vinyl CH), 
6.92 (d, 2H, J = 8.9 Hz, ArH), 6.96 (d, 2H, J = 8.8 Hz, ArH),  7.30 (d, 2H, J = 8.8 Hz, 
ArH), 7.86 (d, 2H, J = 8.9 Hz,  ArH).  13C NMR (75.5 MHz, CDCl3): δ = 55.3, 55.4 
(OCH3), 94.2 (C), 101.6 (CH2), 113.7, 114.2 (CH), 120.1, 124.5 (C), 129.4, 130.3, 
131.7 (CH), 142.2, 149.3, 159.9, 160.4 (C).  IR (KBr): v = 3090, 2996, 2834, 1789 
(w), 1638 (m), 1574 (w), 1489 (s), 1436 (m), 1307 (w), 1207  (m), 1250, 1178 (s), 
1161, 1111 (m), 1029 (s), 1114 (m), 975 (s), 943 (m), 834 (s), 795 (w), 736 (m), 635 
(w), 528 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 386 (M, 81Br], 384 ([M, 79Br]+, 
100), 365 (08), 332 (07), 281 (13), 207 (100), 175 (9), 135 (4). HRMS (ESI+): calcd 
for C19H18N2BrO2 [M+1, 81Br]+: 387.05278; found 387.05244, calcd for C19H18 






4-Bromo-3,5-bis(2,6-dimethoxyphenyl)-1-vinyl-1H-pyrazole (11b): Following the 
General procedure compound 11b was prepared from 8b 
(165 mg, 0.50 mmol), Pd(PPh3)4 (29 mg, 5 mol%), 1,4-







2,6-dimethoxyphenylboronic acid (182 mg, 1 mmol) as a  colourless oil. (137 mg, 
62%). 1H NMR (250 MHz, CDCl3):   = 3.62 (s, 6 H, 2OCH3), 3.63 (s, 6H, 2OCH3), 
4.52 (d, 1H, J = 8.7 Hz, vinyl), 5.55 (d, 1H, J = 15.5 Hz, vinyl), 6.47-6.57 (m, 5H), 
7.11-7.29 (m, 2H, ArH). 13C NMR (75.5 MHz, CDCl3) :  = 56.0 (2OCH3), 56.1 
(2OCH3), 99.7 (CH2), 100.2 (C), 104.1, 104.2 (CH), 105.7, 109.9 (C), 130.4, 131.0, 
131.9 (CH), 135.1, 145.9, 159.0, 159.3 (C). IR (KBr): v = 3086, 2957, 2837, 1645 
(w), 1558 (m), 1472 (s), 1431 (m), 1384 (w), 1334 (m), 1277 (w), 1248 (s), 1174 (w), 
1107 (s), 1082, 977, 822 (m), 773, 729, 636 (s), 589 (m) cm-1. GC-MS (EI, 70 eV): 
m/z (%) = 444 ([M]+, 79Br, 24), 415 (04), 365 (100), 319 (04), 223 (03), 190 (05). 
HRMS (EI, 70 eV): calcd for C21H21N2BrO4 [M, 79Br]+:]+: 444.06846; found  
444.06837. 
 
4-Bromo-3,5-bis(3,5-dimethoxyphenyl)-1-vinyl-1H-pyrazole(11c): Following the 
General procedure compound 11c was prepared from 
8b (165 mg, 0.50 mmol), Pd(PPh3)4 (29 mg, 5 mol%), 
1,4-dioxane/H2O (4:1, 5 mL), K3PO4 (318 mg, 1 
mmol) and 3,5-dimethoxyphenylboronic acid (182 
mg, 1 mmol) as a  white solid, m.p 151-152°C. (165 
mg, 74%). 1H NMR (250 MHz, CDCl3):  = 3.68 (s, 12H, 4OCH3), 4.58 (d, 1H, J = 
8.7 Hz, vinyl), 5.60 (d, 1H, J = 15.5 Hz, vinyl), 6.52-6.62 (m, 5H), 7.16-7.34 (m, 2H, 
ArH). 13C NMR (75.5 MHz, CDCl3):  = 56.0 (2OCH3), 56.1 (2OCH3), 99.7 (CH2), 
100.2 (C), 104.1, 104.2 (CH), 105.7, 109.9 (C), 130.4, 131.0, 131.9 (CH), 135.1, 
145.9, 159.0, 159.3 (C). IR (KBr): v = 3086, 2957, 2837, 1645 (w), 1601 (m), 1584, 
1472 (s), 1431, 1334 (m), 1277 (w), 1248 (s), 1174 (w), 1107 (s), 1082, 977, 882 (m), 
773, 729, 636 (s), 590 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 446 ([M, 81Br], 24), 
444 ([M, 79Br]+, 24), 415 (04), 365 (100), 319 (04), 223 (03), 190 (05). HRMS (EI, 70 













1-Benzyl-4-bromo-3,5-bis(4-fluorophenyl)-1H-pyrazole (11d): Following the 
General procedure compound was prepared from 8a (198 mg, 
0.50 mmol), Pd(PPh3)4 (29 mg, 5 mol%), 1,4-dioxane/H2O (4:1, 
5 mL), K3PO4 (318 mg, 1.5 mmol) and 4-fluorophenylboronic 
acid (140 mg, 1 mmol) as a colourless oil (140 mg, 66%). 1H 
NMR (300 MHz, CDCl3):   = 5.20 (s, 2H, CH2), 6.95-6.98 (m, 
2H, ArH), 7.03-7.09 (m, 4H, ArH), 7.17-7.23 (m, 5H, ArH), 
7.84-7.89 (m, 2H, ArH). 19F NMR (300 MHz, CDCl3):   = -
113.5, -110.8. 13C NMR (62.9 MHz, CDCl3) : = 53.9 (CH2), 114.3 (d, JF,C  = 21.5 
Hz, CH), 115.0 (d, JF,C = 21.8 Hz, CH), 123.7 (CH), 1123.9 (C), 126.8 (CH), 127.5 (d, 
JF,C = 8.1 Hz, CH), 128.6 (CH), 126.8 (C), 131.9 (d, JF,C  = 8.4 Hz, CH), 135.6, 141.3, 
146.6, 160.3 (C), 163.7 (d, JF,C  = 249.0 Hz, CF), 164.3 (d, JF,C  = 248.6 Hz, CF). IR 
(KBr): v = 3061, 2956, 1900, 1667, 1590 (w), 1486 (s), 1446 (m), 1348 (w), 1222 (s), 
1177 (w), 1156 (s), 1012 (m), 948 (w), 840 (s), 787 (m), 722 (s), 650 (m), 575 (w) cm-
1. GC-MS (EI, 70 eV): m/z (%) = 424 ([M]+, 79Br, 49), 349 (06), 329 (11), 225 (38), 








3,4,5-Tris(3,5-dimethylphenyl)-1-vinyl-1H-pyrazole (12a): Following the General 
procedure compound 12a was prepared from 8b (152 mg, 
0.50 mmol), Pd(PPh3)4 (58 mg, 10 mol%), 1,4-dioxane/H2O 
(4:1, 5 mL), K3PO4 (477 mg, 2.25 mmol) and 3,5-
dimethylphenylboronic acid (263 mg, 1.75 mmol) as a light 
yellow oil (116 mg, 57%). 1H NMR (300 MHz, CDCl3):  = 
2.06 (s, 6H, 2CH3), 2.10 (s, 6H, 2CH3), 2.15 (s, 6H, 2CH3), 4.69 (d, 1H, J = 8.7 Hz, 
vinyl), 5.78 (d, 1H, J = 15.3 Hz, vinyl), 6.61- 6.90 (m, 8H), 7.09 (brs, 2H, ArH).  13C 
NMR (75 MHz, CDCl3): δ = 21.1, 21.2, 21.3 (CH3), 100.5 (CH2), 120.5 (C), 126.2, 
128.1, 128.2, 128.5 (CH), 129.2 (C), 129.3, 130.3, 130.4 (CH), 132.6, 133.0, 137.0, 
137.4, 137.8, 141.8, 150.4 (C). IR (KBr): v = 3002, 2915, 2859 (w), 1738, 1642 (m), 
1600 (s), 1550 (w), 1444 (m), 1373 (s), 1303, 1268 (w), 1237 (s), 1203, 1154, 1110, 
1096 (w), 1093 (m), 996, 900, 881 (w), 848 (s), 789 (w), 691 (m), 542 (w) cm-1. GC-
MS (EI, 70 eV): m/z (%) = 406 ([M]+, 100), 391 (26), 375 (02), 259 (04), 203 (03), 
NN
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Following the General procedure compound was 
prepared from 8a (198 mg, 0.50 mmol), Pd(PPh3)4 (58 
mg, 10 mol%), 1,4-dioxane/H2O (4:1, 5 mL), K3PO4 
(477 mg, 2.25 mmol) and 4-
chloromethoxyphenylboronic acid (273 mg, 1.75 
mmol) as a white solid (122 mg, 50%), m.p 155-
157°C. 1H NMR (300 MHz, CDCl3):  = 5.20 (s, 2H, 
CH2), 684-6.87 (m, 2H, ArH), 6.92-6.95 (m, 2H, ArH), 7.00-7.08 (m, 4H, ArH), 7.17-
7.22 (m, 7H, ArH), 7.31-7.34 (m, 2H, ArH). 13C NMR (75 MHz, CDCl3):  = 53.2 
(CH2), 127.1, 127.7 (CH), 128.0 (C), 128.6, 128.8, 128.9, 129.0, 129.5(CH), 130.9, 
131.2, 131.4(C), 131.5, (CH), 132.7, 133.6, 135.1, 136.9, 141.4, 147.8 (C). IR (KBr): 
v = 3089, 3031, 1913, 1601, 1496 (w), 1441 (m), 1391, 1268 (w), 1152 (m), 1089 (s), 
1031 (w), 1008, 980 (s), 956 (w), 841 (s), 784 (w), 734 (s), 609 (w), 542 (s) cm-1. GC-
MS (EI, 70 eV): m/z (%) = 490 ([M, 35Cl, 35Cl, 37Cl]+, 96), 488 ([M, 35Cl, 35Cl, 35Cl]+, 
100), 343 (13), 327 (22), 277 (39), 246 (22), 198 (23). HRMS (EI, 70 eV): calcd for 
C28H19N2Cl3 [M, 35Cl, 35Cl, 37Cl]+: 490.05788; found 490.057812, calcd for C28H19 







the General procedure compound 12c was prepared 
from 8a (198 mg, 0.50 mmol), Pd(PPh3)4 (58 mg, 10 
mol%), 1,4-dioxane/H2O (4:1, 5 mL), K3PO4 (477 mg, 
2.25 mmol) and 4-Ethylphenylboronic acid (262 mg, 
1.75 mmol) as a colourless oil (136 mg, 58%). 1H NMR 
(300 MHz, CDCl3):  =1.08-1.17 (m, 9H, 3CH3), 2.46-
2.58 (m, 6H, 3CH2), 5.20 (s, 2H, CH2), 689-7.05 (m, 
12H, ArH), 7.13-7.19 (m, 3H, ArH), 7.33-7.36 (m, 2H, ArH). 13C NMR (62.9 MHz, 
CDCl3):  = 15.1, 15.2, 15.4 (CH3), 28.4, 28.5, 28.6, 53.2 (CH2), 127.1, 127.3, 
127.4(CH), 127.5(C), 127.6(CH), 127.8(C), 128.1, 128.4, 130.2, 130.3 (CH), 130.7, 
NN
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131.1, 137.8, 141.8, 142.4, 143.1, 144.4, 148.9 (C). IR (KBr): v = 3063 (w), 2962 (m), 
2871, 1910, 1524 (w), 1494, 1452 (s), 1373 (m), 1253, 1155, 1062, 981 (w), 957 (m), 
837 (s), 792 (m), 724, 694 (s), 595, 536 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 470 
([M]+, 02), 446 (16), 366 (100), 351 (08), 289 (12), 261 (12). HRMS (EI, 70 eV): 
calcd for C34H34N2 [M ]+ : 470.27215; found 470.27208. 
 
General procedure for the synthesis of 16 a-i 
A 1,4-dioxane solution of the arylboronic acid, K3PO4, Pd(PPh3)4 and 14 was stirred 
at 110 °C for 4 h under argon atmosphere. After cooling to 20 °C, a saturated aqueous 
solution of NH4Cl was added. The organic and the aqueous layer were separated and 
the latter was extracted with CH2Cl2. The combined organic layers were dried 
(Na2SO4), filtered and the filtrate was concentrated in vacuo. The residue was purified 
by column chromatography. 
 
2',4''-Sulfonyl-bis(4-methylbiphenyl) (16a): Starting with 14 (205 mg, 0.4 mmol), 
K3PO4 (254 mg, 1.2 mmol), Pd(PPh3)4, (6 mol%), 4-
methylphenylboronic acid (135 mg, 1.0 mmol) and 1,4-
dioxane (2 mL), 16a was isolated as a white solid (111 mg, 
70%), m.p 131 °C.1H NMR (300 MHz, CDCl3):   = 2.29 (s, 
3H, CH3), 2.30 (s, 3H, CH3), 6.77-6.80 (m, 2H, ArH), 6.89-
6.92 (m, 2H, ArH), 7.11-7.20 (m, 7H, ArH), 7.26-7.33 (m, 2H, ArH), 7.44-7.48 (m, 
2H, ArH), 8.31-8.35 (m, 1H, ArH). 13C NMR (75.5 MHz, CDCl3):   = 21.2, 21.3 
(CH3), 126.6, 127.1, 127.6, 127.8, 128.2, 128.5, 129.8, 130.0, 132.8, 132.9 (CH), 
135.4, 136.5, 137.4, 138.5, 139.3, 140.1, 142.3, 145.3 (C). IR (KBr): v = 3058, 2921, 
2854,1731 (w), 1613, 1484, 4163, 1404, 1392 (m), 1313 (s), 1247 (w), 1151 (s), 1091, 
959 (w), 820 (m), 757 (s), 670 (m), 585 (s), 532 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) 
= 398 ([M]+, 100), 366 (02), 318 (22), 215 (06), 198 (04), 183 (22), 165 (46), 155 






2',4''-Sulfonyl-bis(3-(trifluoromethyl)biphenyl) (16b):  Starting with 14 (205 mg, 
0.4 mmol), K3PO4 (254 mg, 1.2 mmol), Pd(PPh3)4, (6 







1.0 mmol) and 1,4-dioxane (2 mL), 16b was isolated as a white solid (121 mg, 60%), 
m.p 137 °C. 1H NMR (300 MHz, CDCl3):   = 7.17-7.25 (m, 3H, ArH), 7.32-7.65 (m, 
12H, ArH),  8.39-8.42 (m, 1H, ArH). 19F NMR (300 MHz, CDCl3):   = -113.5, -
110.8. 13CNMR (62.9 MHz, CDCl3): 121.6 (C), 124.1 (q, JF,C = 3.7 Hz, CH), 124.6 (q, 
JF,C = 3.7 Hz, CH), 125.2 (q, JF,C = 3.6 Hz, CH), 126.2 (q, JF,C = 3.8 Hz, CH), 126.9 
(d, JF,C  = 278.2 Hz, CF3), 127.3 (CH), 127.5 (d, JF,C = 279.2 Hz, CF3), 127.9, 128.2, 
128.5, 128.9, 129.5 (CH), 130.0 (C), 130.5, 132.4, 133.3, 134.2 (CH), 138.7, 139.6, 
139.9, 140.2, 140.4, 144.4 (C). IR (KBr): v = 3064, 2922, 2852,1565, 1470 (w), 1330 
(s), 1260 (m), 1225 (w), 1147, 1075 (s), 1022 (m), 955, 901 (w), 803, 755 (s), 729 
(w), 699 (s), 677 (m), 618 (w), 591 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 506 
([M]+, 100), 487 (14), 442 (23), 401 (10), 372 (11), 269 (38), 237 (45), 201 (58), 152 
(38). HRMS (EI, 70 eV): calcd for C26H16F6O2S [M ]+ :  506.07697; found 
506.077006. 
 
2',4''-Sulfonyl-bis(2-methoxybiphenyl) (16c): Starting with 14 (205 mg, 0.4 mmol), 
K3PO4 (254 mg, 1.2 mmol), Pd(PPh3)4, (6 mol%), 2-
methoxyphenylboronic acid (152 mg, 1.0 mmol) and 1,4-
dioxane (2 mL), 16c was isolated as a white solid (106 
mg, 62%), m.p 141 °C. 1H NMR (300 MHz, CDCl3):   = 
3.54 (s, 3H, OCH3), 3.58 (s, 3H, OCH3), 6.77-6.93 (m, 8H, ArH), 7.21-7.34 (m, 5H, 
ArH), 7.53-7.61 (m, 2H, ArH), 7.82-7.87 (m, 1H, ArH). 13C NMR (62.9 MHz, CDCl3) 
:   =55.4, 55.5 (OCH3), 110.0, 111.4, 119.1, 120.8, 121.0, 121.2 (CH), 123.8 (C), 
126.6 (CH), 128.3 (C), 129.2, 130.0, 130,5, 130.7, 132.8, 136.1, 136.8 (CH), 139.5, 
141.3, 143.2, 155.9, 156.4, 164.6 (C). IR (KBr): v = 3052, 2924, 2836, 1720 (w), 
1599 (m), 1500 (w), 1465, 1393, 1293, 1231 (m), 1127 (s), 1051 (m), 954 (w), 884 
(w), 834 (m), 751 (s), 690 (m), 595 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 430 
([M]+, 100), 399 (08), 337 (17), 258 (03), 181 (42), 168 (70), 152 (15), 139 (30) cm-1. 









2',4''-Sulfonyl-bis(4-(trifluoromethyl)biphenyl) (16d): Starting with 14 (205 mg, 
0.4 mmol), K3PO4 (254 mg, 1.2 mmol), Pd(PPh3)4, (6 
mol%), 4-(trifluoromethyl)phenylboronic acid (190 mg, 
1.0 mmol) and 1,4-dioxane (2 mL), 16d was isolated as 
a white solid (121 mg, 60%), m. p 151 °C.1H NMR 
(300 MHz, CDCl3):   = 7.01 (d, J = 8.0 Hz, 2H, ArH), 
7.11-7.16 (m, 1H, ArH), 7.21-7.24 (m, 2H, ArH), 7.30-
7.34 (m, 4H, ArH), 7.51-7.65 (m, 6H, ArH), 8.35-8.40 
(m, 1H, ArH). 13CNMR (62.9 MHz, CDCl3): 126.1 (q, JF,C = 3.7 Hz, CH), 124.1 (q, 
JF,C = 3.8 Hz, CH), 126.1 (q, JF,C = 272.1 Hz, CF3), 126.2 (q, JF,C = 271.4 Hz, CF3), 
127.2, 127.6, 128.2, 128.5, 128.6 (CH), 129.8 (C), 130.5 (CH), 130.9 (C), 132.1, 
133.3 (CH), 139.7, 140.2, 140.4, 141.8 (q, JF,C = 1.2 Hz, C), 142.5 (d, JF,C = 1.0 Hz, 
C), 1441 (C). IR (KBr): v = 3060, 2923, 2851, 1915, 1740 (w), 1592 (m), 1490, 1389 
(w) 1323 (s), 1249, 1187 (w), 1155, 1070 (s), 1004 (m), 967, 881 (w), 819 (s), 763 
(m), 742 (s), 719 (m), 677 (w), 570 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 506 
([M]+, 100), 487 (19), 441 (48), 401 (21), 372 (23), 357 (09), 283 (12), 269 (48), 









2',4''-Sulfonyl-bis(4-tert-butylbiphenyl) (16e): Starting with 14 (205 mg, 0.4 
mmol), K3PO4 (254 mg, 1.2 mmol), Pd(PPh3)4, (6 mol%), 
4-tertiaryphenylboronic acid (178 mg, 1.0 mmol) and 1,4-
dioxane (2 mL), 16e was isolated as a white solid (135 
mg, 70%), m. p 160 °C.1H NMR (300 MHz, CDCl3):  = 
1.24 (s, 9H, 3CH3), 1.25 (s, 9H, 3 CH3), 6.81-6.83 (m, 
2H, ArH),  7.07-7.25 (m, 9H, ArH), 7.35 (brs, 2H, ArH),  
7.42-7.46 (m, 2H, ArH), 8.34-8.37 (m, 1H, ArH). 13C NMR (75.5 MHz, CDCl3) :  = 
31.4, 31.6 (3CH3), 34.4, 34.6 (C), 114.9 (CH), 126.0, 126.5, 126.9, 127.5, 128.3, 
128.5, 129.9, 132.7, 132.9 (CH), 135.2, 136.4, 139.2, 140.1, 142.3, 145.0, 150.8, 
151.8 (C). IR (KBr): v = 3060, 2950, 2863, 1608, 1566, 1486, 1434 (w), 1311 (m), 
1245, 1180 (w), 1156 (s), 1093 (m), 1040 (w), 1001, 831 (m), 815, 765, 722 (s). 640 





(02), 257 (06), 226 (35), 198 (12), 165 (17). HRMS (EI, 70 eV): calcd for C32H34O2S 
[M ]+ : 482.22786; found 482.22779. 
 
2',4''-Sulfonyl-bis(4-fluorobiphenyl) (16f): Starting with 14 (205 mg, 0.4 mmol), 
K3PO4 (254 mg, 1.2 mmol), Pd(PPh3)4, (6 mol%), 4-
fluorophenylboronic acid (140 mg, 1.0 mmol) and 1,4-
dioxane (2 mL), 16f was isolated as a colourless oil. (114 
mg, 70%), m. p 131 °C.1H NMR (300 MHz, CDCl3):  = 
1.24 (s, 3H, CH3), 1.25 (s, 3H, CH3), 6.75-6.89 (m, 4H, 
ArH), 7.07-7.11 (m, 3H, ArH), 7.19-7.22 (m, 2H, ArH), 7.27-7.3 (m, 2H, ArH), 7.37-
7.41 (m, 2H, ArH), 7.49-7.52 (m, 2H, ArH) 8.34-8.37 (m, 1H, ArH). 13CNMR (75.5 
MHz, CDCl3): 113.1 (d, JF,C = 22.1 Hz, CH), 115.0 (d, JF,C = 23.0 Hz, CH), 125.7, 
126.9, 127.1, 127.5, 128.0 (d, JF,C = 8.3 Hz, CH), 130.7 (d, JF,C = 8.0 Hz, CH), 131.7, 
132.0 (CH), 133.0 (d, JF,C = 3.0 Hz, C), 134.2 (d, JF,C = 3.0 Hz, C), 138.4, 138.9, 
140.0, 143.5 (C), 161.4 (d, JF,C = 249.0 Hz, CF), 162. 0 (d, JF,C = 249.2 Hz, CF). IR 
(KBr): v = 3060, 2950, 2863, 1608, 1566, 1486, 1434 (w), 1311 (m), 1245, 1180 (w), 
1156 (s), 1093 (m), 1040 (w), 1001, 831 (m), 815, 765, 722 (s), 640 (w), 610, 556 (s) 
cm-1. GC-MS (EI, 70 eV): m/z (%) = 406 ([M]+, 100), 342 (21), 321 (20), 233 (05), 
219 (17), 187 (41), 170 (82), 159 (17), 133 (09). HRMS (EI, 70 eV): calcd for 







2',4''-Sulfonyl-bis(4-vinylbiphenyl) (16g): Starting with 14 (205 mg, 0.4 mmol), 
K3PO4 (254 mg, 1.2 mmol), Pd(PPh3)4, (6 mol%), 4-
vinylphenylboronic acid (148 mg, 1.0 mmol) and 1,4-
dioxane (2 mL), 16g was isolated as a colourless oil (110 
mg, 65%). 1H NMR (300 MHz, CDCl3):  = 5.21 (d, J = 
10.8 Hz, 2H, Vinylic CH), 5.69 (dd, J = 12.2, 17.5 Hz, 2H, 
Vinylic CH2), 6.64 (dd, J = 10.8, 17.5 Hz, 2H, Vinylic CH2), 6.85 (d, J = 8.2 Hz, 2H, 
ArH),  7.07-7.10 (m, 3H, ArH), 7.13-7.38 (m, 8H, ArH), 7.47-7.49 (m, 2H, ArH), 
8.32-8.35 (m, 1H, ArH). 13C NMR (75.5 MHz, CDCl3):  = 114.5, 114.8 (CH2), 
125.1, 126.6, 126.9, 127.4, 127.7, 128.3, 128.5, 130.2, 132.5, 132.9, 136.1, 136.4 
(CH), 136.9, 137.7, 137.8, 138.5,  139.3, 140.1, 141.8, 144.9 (C). IR (KBr): v = 3086, 





(s), 1249 (w), 1152 (s), 1092 (m), 1333, 968 (w), 822 (s), 756 (s), 666 (m), 586 (s), 
539 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) = 422 ([M]+, 100), 387 (04), 357 (12), 328 
(07), 255 (05), 195 (13), 178 (44), 151 (15), 117 (06). HRMS (EI, 70 eV): calcd for 
C28H22O2S [M ]+ : 422.13350; found 422.133839. 
 
2',4''-Sulfonyl-bis(3,5-dimethylbiphenyl) (16h): Starting with 14 (205 mg, 0.4 
mmol), K3PO4 (254 mg, 1.2 mmol), Pd(PPh3)4, (6 
mol%), 3,4-Dimethylphenylboronic acid (150 mg, 1.0 
mmol) and 1,4-dioxane (2 mL), 16h was isolated as a 
white solid (102 mg, 60%), m. p 135 °C. 1H NMR (300 
MHz, CDCl3):   = 2.06 (s, 6H, 2CH3), 2.26 (s, 6H, 
2CH3), 6.44 (s, 2H, ArH), 6.82 (s, 1H, ArH), 6.29 (s, 1H, ArH), 7.03-7.09 (m, 3H, 
ArH), 7.17-7.19 (m, 2H, ArH), 7.27-7.30 (m, 2H, ArH), 7.42-7.46 (m, 2H, ArH), 
8.32-8.35 (m, 1H, ArH). 13C NMR (75.5 MHz, CDCl3):  = 21.2 (2CH3), 21.4 (2CH3), 
125.2, 126.8, 127.5 (CH), 127.6 (C), 127.8, 128.3, 128.5, 129.1, 130.1, 132.5, 132.8 
(CH), 136.8, 138.0, 138.5, 139.4, 139.6, 140.0, 142.5 (C). IR (KBr): v = 3085, 2917, 
2855 (w),1589 (m), 1556 (w), 1467 (m), 1388 (w), 1302 (s), 1249 (w), 1151 (s), 1125 
(m), 995 (w), 853 (m), 831 (s), 777, 699 (m), 586 (s), 562 (s) cm-1. GC-MS (EI, 70 
eV): m/z (%) = 426 ([M]+, 100), 408 (16), 347 (31), 317 (11), 281 (05), 197 (10), 165 















General procedure for double Heck cross-coupling reactions.  
In a pressure tube (glass bomb) a DMF suspension (5 mL) of Pd (OAc) 2 (12 mg, 0.05 
m mol, 2.5 mol% per Br) and dicyclohexyl (2', 4’, 6’-triisopropylbiphenyl-2-yl) 
phosphine (L2) (47 mg, 0.10 m mol), or of the same amount of the other ligand 
Indicated, was purged with argon and stirred at 20 °C to give a yellowish or brownish 
transparent solution. To the stirred solution were added the dibromopyridine (199 mg, 
1.0 m mol), NEt3 (1.1 mL, 8.0 m mol) and the acryl ate or styrene (1.25 equiv. per 
Br). The reaction mixture was stirred at 120 °C for 48 h. The solution was cooled to 
20 °C, poured into H2O and CH2Cl2 (25 mL each), and the organic and the aqueous 
layer were separated. The latter was extracted with CH2Cl2 (3 x 25 mL). The 
combined organic layers were washed with H2O (3 x 20 mL), dried (Na2SO4), filtered 
and concentrated in vacuo. The residue was purified by chromatography (flash silica 
gel, heptanes/EtOAc).  
 
(2E,2'E)-Dimethyl 3,3'-(pyridine-2,3-diyl)diacrylate (19a).  
Compound 19a was prepared starting with 2,3-dibromopyridine  
(17), (237 mg, 1.0 mmol) as a light yellow oil (175 mg, 71%). 1H 
NMR (300 MHz, CDCl3):  = 3.76 (s, 3H, OCH3), 3.77 (s, 3H, 
OCH3),  6.34 (d, J = 15.2 Hz, 1H, CH), 7.01 (d, J = 15.6 Hz, 1H, 
CH), 7.22-7.26 (m, 1H, ArH), 7.77 (dd, J = 1.5, 8.2 Hz, 1H, ArH), 7.93 (d, J = 15.4 
Hz, 1H, CH), 8.00 (d, J = 15.4 Hz, 1H, CH), 8.56 (dd, J = 1.7, 4.6 Hz, 1H, ArH). 13C 
NMR (62.9 MHz, CDCl3):  = 51.8, 51.9 (OCH3), 123.0, 124.3, 124.6 (CH), 130.1 
(C), 134.9, 138.6, 139.2, 150.7 (CH), 150.9, 166.2, 167.0 (C). IR (KBr): v = 2955, 
2929, 2852 (w), 1722, 1709 (s), 1634 (m), 1580, 1555 (w), 1434 (s), 1361(w), 1300, 
1275, 1194, 1161 (s), 1086, 1064, 1010, 990 (w), 970, (m), 932, 870, 778 (m), 732, 
720, 702, 605, 582, 568, 544 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 247 ([M]+, 2), 
216 (19), 188 (100), 156 (28), 144 (24), 78 (6). HRMS (EI, 70 eV): calcd for 







  (2E,2'E)-Diethyl 3,3'-(pyridine-2,3-diyl)diacrylate (19b). Compound 19b was 
prepared starting with 2,3-dibromopyridine  (17), (237 mg, 1.0 
mmol) as a white solid (195 mg, 71%), m.p = 145-147 °C. 1H 
NMR (300 MHz, CDCl3):  = 1.26 (t, J = 7.1 Hz, 3H, CH3), 
1.27 (t, J = 7.1 Hz, 3H, CH3), 4.19 (q, J = 7.1, 14.3 Hz, 2H, 
CH2O), 4.22 (q, J = 7.1, 14.3 Hz, 2H, CH2O), 6.30 (d, J = 15.2 Hz, 1H, CH), 6.99 (d, 
J = 15.2 Hz, 1H, CH), 7.20-7.25 (m, 1H, ArH), 7.76 (dd, J = 1.4, 8.1 Hz, 1H, ArH), 
7.89-7.99 (m, 2H, ArH), 8.53 (dd, J = 1.6, 4.6 Hz, 1H, ArH). 13C NMR (75 MHz, 
CDCl3):  = 14.2 (2CH3), 60.7, 60.8 (CH2O), 123.5, 124.3, 125.1 (CH), 130.1 (C), 
134.9, 138.4, 150.7 (CH), 150,8 (C), 165.8, 166.5 (CO). IR (KBr): v = 1705, 1631 (s), 
1580, 1552, 1473, 1446 (w), 1423, 1364 (m), 1295 (s), 1228 (m), 1661 (s), 1112, 
1065 (w), 1027, 971, 892, 872, 808, 782 (s), 722, 709, 602, 580, 546 (m) cm-1. GC-
MS (EI, 70 eV): m/z (%) = 275 ([M]+, 3), 246 (02), 230 (30), 202 (100), 174 (48), 156 








 (2E,2'E)-Diisobutyl 3,3'-(pyridine-2,3-diyl)diacrylate (19c). Compound 19c was 
prepared starting with 2,3-dibromopyridine  (17), (237 mg, 
1.0 mmol) as a light yellow semisolid (271 mg, 82%). 1H 
NMR (300 MHz, CDCl3):  = 0.89 (d, 6H, J = 6.8 Hz, 
2CH3), 0.93 (d, 6H, J = 6.7 Hz, 2CH3), 1.90-2.00  (m, 2H), 
3.93 (d, 2H, J = 6.7 Hz, CH2), 3.96 (d, 2H, J = 6.7 Hz, CH2), 6.33 (d, H, J = 15.6 Hz), 
7.01 (d, H, J = 15.9 Hz), 7.20-7.25 (m, H, ArH), 7.80 (dd, H, J = 1.5, 8.0 Hz, ArH), 
7.95 (d, H, J = 15.2 Hz, H), 8.00 (d, H, J = 15.8 Hz, H), 8.55 (dd, H, J = 1.6, 4.5 Hz, 
ArH). 13C NMR (75 MHz, CDCl3):   = 19.0, 19.1 (CH3), 27.8 (CH), 70.8, 71.0 
(CH2O), 123.5, 124.3, 125.2 (CH), 130.1 (C), 135.0, 138.4, 139.0, 150.6 (CH), 150.8,  
165.1, 165.8(C). IR (KBr): v = 2960, 2874 (m), 1712 (s), 1635, 1469, 1424, 1376, 
1369 (m), 1305, 1292, 1276, 1256, 1158, 1010, 973 (s), 802, 780, 702, 606, 590 (m) 
cm-1. GC-MS (EI, 70 eV): m/z (%) = 331 ([M]+, 02), 258 (46), 230 (100), 202 (29), 
174 (81), 156 (19), 129 (38). HRMS (EI, 70 eV): calcd for C19H25O4N [M]+: 







  (2E,2'E)-Di(tert-butyl) 3,3'-(pyridine-2,3-diyl)diacrylate (19d). Compound 19d 
was prepared starting with 2,3-dibromopyridine  (17), (237 mg, 
1.0 mmol) as a light yellow solid (278 mg, 84%), m.p = 137-
138 °C. 1H NMR (300 MHz, CDCl3):  = 1.43 (s, 9H, 3CH3), 
1.44 (s, 9H, 3CH3), 6.22 (d, J = 15.2 Hz, 1H, CH), 6.90 (d, J = 
15.9 Hz, 1H, CH), 7.17-7.22 (m, 1H, CH ArH), 7.73 (dd, J = 1.7, 8.0 Hz, 1H, ArH), 
7.84 (d, J = 15.2 Hz, 1H, CH), 7.86 (d, J = 15.8 Hz, 1H, CH), 8.50 (dd,  J = 1.7, 4.6 
Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3):   = 28.0 (3CH3), 28.1 (3CH3), 80.7, 
81.0 (C), 124.0, 125.3, 127.0 (CH), 130.1 (C), 134.9, 137.6, 138.0, 150.4 (CH), 150.9 
(CH), 164.9, 165.7 (CO). IR (KBr): v = 3004, 2978, 2930, 2871 (w), 1698 (s), 1634, 
1578, 1552, 1471, 1456 (w), 1422, 1392, 1365, 1392 (m), 1365, 1309, 1254, 1138 (s), 
1086, 1062, 1039 (w), 971 (s), 922, 889, 845, 805, 763, 731, 598, 538 (m) cm-1. GC-
MS (EI, 70 eV): m/z (%) = 331 ([M]+, 1), 275 (1), 230 (23), 202 (39), 174 (99), 130 








(2E,2'E)-Di(2-ethylhexyl) 3,3'-(pyridine-2,3-diyl)diacrylate (19e). Compound 19e 
was prepared starting with 2,3-dibromopyridine  (17), 
(237 mg, 1.0 mmol) as a light yellowish oil (265 mg, 
60%). 1H NMR (300 MHz, CDCl3):  = 0.82–0.87 (m, 
12 H, 4CH3), 1.27-1.31 (m, 12H, 6CH2), 1.28-1.31 
(m, 4H, 2CH2), 1.33-1.60 ( m, 2H, CH), 4.06-4.09 (m, 4H, 2CH2O), 6.31 (d, 15.2 Hz, 
1H, CH), 7.01 (d, J = 15.2, 1H, CH), 7.20-7.25 (m, 1H, ArH), 7.78 (dd, J = 1.5, 8.0 
Hz, 1H, ArH), 7.92 (d, J = 15.2 Hz, 1H, CH), 7.97 (d, J = 15.2 Hz, 1H, CH), 8.55 (dd, 
J = 1.8, 4.5 Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3):   = 10.9, 11.0, 14.0 (CH3), 
22.9, 23.8 28.9, 30.4 (CH2), 38.7, 38.8 (CH), 67.1, 67.4 (CH2O), 123.6, 124.2, 125.2 
(CH),  138.3 (C), 135.0, 138.4, 138.9, 150.6 (CH), 150.9 (C), 165.9, 166.6 (CO). IR 
(KBr): v = 2957, 2927, 2872, 2869 (m), 1713 (s), 1636, 1580, 1554, 1460, 1425, 1380 
(w), 1296, 1260 (m), 1220, 1204 (w), 1163 (s), 1085, 1063, 1027, 1014 (w), 974 (m), 







443 ([M]+, 2), 398 (04), 332 (42), 286 (100), 202 (48), 70 (16), 57 (29). HRMS (EI, 
70 eV): calcd for C27H41O4N [M]+: 443.30301; found 443.30301.  
 
2,3-Di(2-phenylethenyl)pyridine (19f). Compound 17f was prepared starting with 
2,3-dibromopyridine  (17), (237 mg, 1.0 mmol) as a light yellow 
solid (204 mg, 72%), m.p = 130-132 °C 1H NMR (300 MHz, 
CDCl3):  = 6.88 (d, J = 15.2 Hz, 1H, CH), 7.06 (dd, J = 7.9, 4.5 
Hz, 1H, ArH), 7.21-7.31 (m, 6H, ArH), 7.36-7.45 (m, 4H, ArH), 
7.49-7.52 (m, 2H, ArH), 7.69-7.74 (m, 2H, ArH), 8.44 (dd, J = 1.8, 4.5 Hz, 1H, ArH). 
13C NMR (62.9 MHz, CDCl3):  = 122.3, 124.2, 124.4, 126.8, 127.3, 128.3, 128.4, 
128.7, 128.9, (CH), 131.4 (C), 133.1, 134.4, 134.7 (CH), 137.0, 148.4, 152.5 (C). IR 
(KBr): v  = 3078, 3055, 3024, 2929, 1732, 1699, 1628, 1597, 5174 (w), 1492, 1448, 
1419 (m), 1371, 1323, 1300, 1271, 1240, 1203, 1179, 1162, 1072, 1045, 1027 (w), 
958 (s), 915, 847 (w), 770, 744, 687 (s), 543 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 
283 ([M]+, 100), 206 (42), 180 (07), 134 (06), 91 (04), 77 (03). HRMS (EI, 70 eV): 
calcd for C21H16N [M-1]+:  282.12783; found 282.12783. 
N
 
2,3-Di[2-(4-methoxyphenyl)ethenyl]pyridine (19g). Compound 19g was prepared 
starting with 2,3-dibromopyridine  (17), (237 mg, 1.0 mmol) 
as a light yellow crystalline solid (271 mg, 79%), m.p = 123-
124 °C 1H NMR (300 MHz, CDCl3):  = 3.75 (s, 3H, OCH3), 
3.76 (s, 3H, OCH3), 6.81-6.88 (m, 5H, ArH), 7.03-7.07 (m, 
1H, ArH), 7.30 (d, J = 15.7 Hz, 1H, CH), 7.31 (d, J = 15.2 
Hz, 1H, CH), 7.39-7.49 (m, 4H, ArH), 7.64 (d, J = 15.2 Hz, 1H, CH), 7.72 (dd, J = 
1.6, 8.0 Hz, 1H, ArH), 8.42 (dd, J = 1.5, 4.6 Hz, 1H, ArH). 13C NMR (62.9 MHz, 
CDCl3):  = 55.3, 55.3 (OCH3), 114.1, 114,2 , 121.9, 122.1, 122.3, 127.9, 128.6, 
(CH),  129.3, 130.3 (C), 132.3, 133.9, 134.1, 148.0 (CH), 156.0, 159.7, 159.9 (C). IR 
(KBr): v = 3045, 3000, 2668, 2932, 2836, 1692, 1626(w), 1600, 1572 (m), 1550 (w), 
1508 (s), 1464, 1455, 1439, 1426 (m), 1344, 1332 (w), 1245, 1170 (s), 1023, 967 (m), 





(%) = 343 ([M]+, 100), 236 (72), 222 (09), 121 (31), 77 (2). HRMS (EI, 70 eV): calcd 
for C23H21O2N [M]+: 343.15668; found  343.15642. 
 
2,3-Di[2-(4-methylphenyl)ethenyl]pyridine (19h). Compound 19h was prepared 
starting with 2,3-dibromopyridine  (17), (237 mg, 1.0 mmol) as a 
light yellow semisolid (202 mg, 65%). 1H NMR (300 MHz, 
CDCl3):  = 2.27 (s, 3H, CH3), 2.28 (s, 3H, CH3), 6.85 (d, J = 
15.2 Hz, 1H, CH), 7.03-7.14 (m, 5H, ArH), 7.32-7.43 (m, 6H, 
ArH), 7.64-7.72 (m,  2H, ArH), 8.42 (dd, J = 1.5, 4.5 Hz, 1H, ArH). 13C NMR (75 
MHz, CDCl3):  = 21.3, 21.4 (CH3), 122.0, 123.3, 123.5, 126.6, 127.2, 129.4 (CH), 
129.5 (C), 129.6 (CH), 131.5 (C), 132.8, 134.2  (CH), 134.3 (C), 134.5 (CH), 138.2, 
138.4 (C), 148.2 (CH), 152.6 (C). IR (KBr): v = 3031, 2919, 2853, 2727, 1693, 1626, 
1605, 1573, 1550, 1450 (w), 1422 (m), 1324, 1298, 1200, 1182, 1109, 1082, 1039, 
1018 (w), 959 (s), 867 (w), 805 (s), 706, 635, 613, 548 (w), 533 (m) cm-1. GC-MS 
(EI, 70 eV): m/z (%) = 311 ([M]+, 60), 310 (100), 220 (45), 147 (06), 105 (09). HRMS 
(EI, 70 eV): calcd for C23H21N [M]+:  311.15903 found 311.15912. 
N
 
 (2E,2'E)-Dibutyl 3,3'-(2,2'-bipyridine-5,5'-diyl)diacrylate (21a). Compound 20a 
was prepared starting with 2,5-
dibromopyridine  (20), (237 mg, 1.0 mmol) 
as a white solid (169 mg, 83%), m.p = 225-
227 °C.  1H NMR (250 MHz, CDCl3):  = 
0.86 (t, J = 7.3 Hz, 6H, 2CH3), 1.33-1.45 (m, 4H, 2CH2), 1.57-1.69 (m, 4H, 2CH2), 
4.18 (t, J  = 6.7 Hz, 4H, 2CH2O), 6.45 (d, J = 15.2 Hz, 2H, 2CH), 7.61 (d, J = 15.2 
Hz, 2H, 2CH), 7.88 (dd, J = 2.2, 8.4 Hz, 2H, ArH), 8.39 (d, J = 8.3 Hz, 2H, ArH), 
8.70 (d, J = 1.9 Hz, 2H, ArH). 13C  NMR (62.9 MHz, CDCl3): = 13.6 (CH3), 19.2, 
29.7 (CH2), 64.7 (CH2O), 120.6, 121.3 (CH), 130.5 (C), 135.0, 140.0, 149.4 (CH), 
156.4, 166.4 (C). IR (KBr): v = 3055, 2957, 2933, 2872 (w), 1714, 1635, 1469, 1377, 
1303 (s), 1250, 1200 (m), 1168, 1140, 1117  (s), 1056, 1020, 989, 976, 953, 925, 900, 








([M]+, 100), 363 (24), 336 (65), 279 (70), 178 (11). HRMS (EI, 70 eV): calcd for 
C24H28O4N2 [M]+: 408.20436; found  408.20450. 
 
(2E,2'E)-Dihexyl 3,3'- (2,2'-bipyridine-5,5'-diyl)diacrylate (21b). Compound 21b 
was prepared starting with 2,5-
dibromopyridine (20), (165 mg, 1.0 
mmol) as a white solid (329 mg, 71%), 
m.p = 215-217 °C  1H NMR (300 MHz, 
CDCl3): = 0.83 (t J = 6.57 Hz, 6H, 2CH3), 1.17-1.35 (m, 12H, 6CH2), 1.59-1.69 (m, 
4H, 2CH2), 4.15 (t, J = 6.7 Hz, 4H, 2CH2O), 6.49 (d, J = 15.2 Hz, 2H, 2CH), 7.63 (d, 
J = 15.2 Hz, 2H, 2CH), 7.89 (d, J = 8.3 Hz, 2H, ArH), 8.40 (d, J = 8.3 Hz, 2H, ArH), 
8.70 (brs, 2H, ArH). 13C NMR (75 MHz, CDCl3): = 13.9 (CH3), 22.5, 25.6, 28.6, 
31.4 (CH2), 65.0 (CH2O), 120.6, 121.3 (CH), 130.5 (C), 135.0, 140.4, 149.3 (CH), 
156.3 (C), 166.4 (CO). IR (KBr): v = 2952, 2928, 2870 (m), 1714, 1635 (s),1592,1544 
(w), 1468, 1376 (m), 1304 (s), 1273, 1250, 1214, 1199 (w), 1171, 1139 (s), 1067, 
1013 (w), 990, 975 (m), 931, 899, 879, 863 (w), 834 (m), 815 (w), 724, 708, 652 (m), 
599, 538, 529 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 464([M]+,73), 407 (17), 363 
(100), 336 (91), 324 (34), 279 (65), 205 (14), 57 (13). HRMS (EI, 70 eV): calcd for 









Compound 21c was prepared starting with 
2,5-dibromopyridine (20), (237 mg, 1.0 
mmol), following the general procedure, as a 
white solid (213 mg, 82 %), m.p = 255-257 
°C 1H NMR (250 MHz, CDCl3):  = 0.82-0.90 (m, J = 12H, 4CH3), 1.18-1.39 (m, 
16H, 10CH2), 1.59-1.69 (m, 2H, 2CH), 4.08-4.10 (m, 4H, 2CH2O), 6.51 (d, J = 15.2 
Hz, 2H, 2CH), 7.64 (d, J = 15.2 Hz, 2H, 2CH), 7.91 (dd, J = 2.2, 8.4 Hz, 2H, ArH), 
8.39 (d, J = 8.3 Hz, 2H, ArH), 8.72 (brs, 2H, ArH). 13C NMR (62.9 MHz, CDCl3):  = 
11.0, 14.0 (CH3), 23.0, 23.8, 28.9, 30.4 (CH2), 38.8 (CH), 67.2 (CH2O), 120.6, 121.3 








2926, 2858, 1709, 1633 (s), 1568, 1468, 1379 (m), 1302 (s), 1254 (m), 1162(s), 1135 
(m), 1050, 1005 (w), 839 (m), 767, 748, 729, 709, 546 (w) cm-1. GC-MS (EI, 70 eV): 
m/z (%) =  520 ([M]+, 21), 491 (6), 408 (14), 391 (37), 364 (22), 296 (100), 205 (7). 
HRMS (EI, 70 eV): calcd for C32H44N2O4: 520.33011; found 520.33045. 
 
(2E,2'E)-Di(tert-butyl) 3,3'-(2,2'-bipyridine-5,5'-diyl)-diacrylate (21d). Compound 
21d was prepared starting with 2,5-
dibromopyridine (20), (237 mg, 1.0 mmol) as a 
white solid (342 mg, 84%), m.p = 237-238 °C  
1H NMR (300 MHz, CDCl3): = 1.47 (s, 18H, 
6CH3), 6.43 (d, J = 15.2 Hz, 2H, 2CH), 7.56 
(d, J = 15.2 Hz, 2H, 2CH), 7.89 (dd, J = 2.2, 8.4 Hz, 2H, ArH), 8.39 (d, J = 8.3 Hz, 
2H, ArH), 8.71 (d, J = 2.0 Hz, 2H, ArH). 13C NMR (75 MHz, CDCl3): = 28.2 
(CH3), 81.0 (C), 121.3, 122.5 (CH), 130.7 (C), 135.0, 139.3, 149.2 (CH), 156.1 (C), 
156.5 (CO). IR (KBr): v = 3006, 2976, 2928, 2855 (w), 1699 (s), 1667 (w), 1634 (m), 
1555, 1544 (w), 1468, 1455, 1363, 1315, 1251, 1208 (m), 1146 (s), 1054, 1023 (m), 
993, 981, 835 (s), 765, 750, 738, 710, 650 (m), 589 (w) cm-1. GC-MS (EI, 70 eV): m/z 
(%) = 408 ([M]+, 24), 352 (27), 296 (100), 205 (10), 279 (40), 252 (80), 205 (10). 









(2E,2'E)-Di(isobutyl) 3,3'-(2,2'-bipyridine-5,5'-diyl)diacrylate (21e). Compound 
21e was prepared starting with 2,5-
dibromopyridine (20), (157 mg, 1.0 mmol) as a 
white solid (314 mg, 77%), m.p = 231-232 °C  
1H NMR (300 MHz, CDCl3): = 0.93 (d, J = 
6.7 Hz, 12H, 4CH3), 1.89-1.97 (m, 2H, 2CH), 
3.94 (d, J = 6.7 Hz, 4H, 2CH2O), 6.53 (d, J = 
15.2 Hz, 2H, 2CH), 7.65 (d, J = 15.2 Hz, 2H, 2CH), 7.91 (d, J = 2.1, 8.4 Hz, 2H, 
ArH), 8.39 (d, J = 8.3, Hz, 2H, ArH), 8.33 (brs, 2H, ArH). 13C NMR (62.9 MHz, 
CDCl3): = 18.1 (CH3), 26.8 (CH),  69.9 (CH2O),  119.6, 120.3 (CH), 129.5 (C), 








(m), 1728 (s), 1679, 1641, 1632, 1590 (w), 1462, 1378 (m), 1235, 1169 (s), 1092, 
984, 945, 800, 784 (m), 648 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 408 ([M]+, 56), 
352 (17), 296 (100), 205(11), 131 (06). HRMS (EI, 70 eV): calcd for 
C24H28N2O4[M]+: 408.2041; found 408.20451. 
 
(2E,2'E)-Dimethyl -3,3'-(pyridine-3,5-diyl)diacrylate (23a). Compound 23a was 
prepared starting with 3,5-dibromopyridine  (22), 
(237 mg, 1.0 mmol) as a white solid (170 mg, 69%), 
m.p = 156-158 °C 1H NMR (300 MHz, CDCl3): = 
3.76 (s, 6H, 2CH3O), 6.46 (d, J = 16.1 Hz, 2H, 2CH), 
7.62 (d, J = 16.1 Hz, 2H, 2CH), 7.86 (brs, 1H, ArH), 8.66 (s, 2H, ArH). 13C NMR 
(62.9 MHz, CDCl3): = 60.0 (CH3O), 121.1, 132.2 (CH), 132.6 (C), 140.3, 150.3 
(CH), 166.4 (CO). IR (KBr): v = 2954, 2921, 2851 (m), 1722, 1716, 1642 (s), 1433, 
1329, 1316, 1329, 1315 (m), 1292, 1278 (w), 1244, 1189 (m), 1169 (s), 1025, 1014, 
999 (w), 977, 854 (m), 785, 738, 727, 704 (w), 688 (m), 600 (m) cm-1. GC-MS (EI, 70 
eV): m/z (%) = 247 ([M]+, 70), 232 (64), 216 (100), 200 (30), 184 (72), 156 (46), 128 




]+, 247.08448 found  247.08498. 
 
(2E,2'E)-Diethyl 3,3'-(pyridine-3,5-diyl)diacrylate (23b). Compound 23b was 
prepared starting with 3,5-dibromopyridine  (22), 
(237 mg, 1.0 mmol) as a white solid (195 mg, 
71%), m.p = 162-163 °C  1H NMR (300 MHz, 
CDCl3): = 1.27 (t, J = 7.0 Hz, 6H, 2CH3), 4.22 (q, J = 7.1, 14.3 Hz, 4H, 2CH2O), 
6.48 (d, J = 16.1 Hz, 2H, 2CH), 7.60 (d, J = 16.1 Hz, 2H, 2CH), 7.88 (s, 1H, ArH), 
8.66 (s, 2H, ArH). 13C NMR (62.9 MHz, CDCl3): = 14.2, (CH3), 60.9 (CH2O), 
121.5 (CH), 130.5 (C), 132.4, 140.0, 150.2 (CH), 156.9( CO). IR (KBr): v = 2982, 
2934, 2904, 2874 (w), 1699 (s), 1639 (m), 1592, 1567 (w), 1420, 1368, 1321, 1239 
(m), 1167 (s), 1094 (m), 977 (s), 911(w), 854 (s), 810 (w), 686 (m), 605, 587, 541 (w) 
cm-1. GC-MS (EI, 70eV): m/z (%) = 275 ([M]+, 51), 246 (61), 230 (100), 200 (44), 
184 (42),  128 (14), 51 (7). HRMS (EI, 70 eV): calcd for C15H17O4N [M]+: 





(2E,2'E)-Dibutyl 3,3'-(pyridine-3,5-diyl)diacrylate (23c). Compound 23c was 
prepared starting with 3,5-
dibromopyridine (22), (237 mg, 1.0 
mmol) as a white solid (271 mg, 
82%), m.p = 148-149 °C  1H NMR 
(300 MHz, CDCl3): = 0.89 (t, J = 7.4 Hz, 6H, 2CH3), 1.30-1.42 (m, 4H, 2CH2), 
1.57-1.67 (m, 4H, 2CH2), 4.15 (t, J = 6.7 Hz, 4H, 2CH2O), 6.49 (d, J = 16.1 Hz, 2H, 
2CH), 7.63 (d, J = 16.1 Hz, 2H, 2CH), 7.89 (s, 1H, ArH), 8.66 (s, 2H, ArH). 13C 
NMR (75 MHz, CDCl3): = 13.6 (CH3), 19.1, 30.7 (CH2), 64.8 (CH2O), 121.4 (CH), 
130.4 (C), 132.3, 139.9, 150.3 (CH), 166.0 (CO). IR (KBr): v = 2957, 2933, 2872, 
1708 (s), 1638 (m), 1567, 1465, 1448, 1432, 1382, 1355, 1342 (w), 1312, 1285, 1258, 
1239 (m), 1168 (s), 1062 (m), 978 (s), 901 (w), 858 (s), 735, 702 (w), 683 (m), 602, 
589 cm-1. GC-MS (EI, 70eV): m/z (%) = 331 ([M]+, 12), 258 (100), 230 (22), 202 




 70 eV): calcd for C19H25O4N [M]+, 
331.17781 found  331.17819. 
 
5
). HRMS (EI, 70 eV): calcd for C19H25O4N [M]+: 331.40610; found 
331.40611. 
 
(2E,2'E)-Di(isobutyl) 3,3'-(pyridine-3, -diyl)diacrylate (23d). Compound 23d was 
prepared starting with 3,5-dibromopyridine 
(22), (237 mg, 1.0 mmol) as a white solid 
(278 mg, 84%), m.p = 147-148 °C  1H 
NMR (300 MHz, CDCl3): = 0.90 (d, J = 6.8 Hz, 12H, 4CH3), 1.88-2.00 (m, 2H, 
2CH), 3.92 (d, J = 6.7 Hz, 4H, 2CH2O), 6.51 (d, J = 16.1 Hz, 2H, 2CH), 7.60 (d, J = 
16.1 Hz, 2H, 2CH), 7.92 (s, 1H, ArH), 8.68 (s, 2H, ArH). 13C NMR (75 MHz, 
CDCl3): = 19.0, (CH3), 27.8 (CH), 70.9 (CH2O), 121.4, (CH), 130.6 (C), 132.3, 
140.0, 150.3 (CH), 166.0 (CO). IR (KBr): v = 2956, 2872 (m), 1708, 100 (s), 1638 
(m), 1573, 1558 (w), 1470, 1435, 1375, 1312, 1293, 1273, 1256, 1240 (m), 1170, 
1020, 980, 858 (s), 799, 732, 706 (w), 682 (s), 590, 552, 534 (w) cm-1. GC-MS (EI, 70 






(2E,2'E)-Dihexyl 3,3'-(pyridine-3,5-diyl)diacrylate (23e). Compound 23e was 
prepared starting with 3,5-
dibromopyridine (22), (237 
mg, 1.0 mmol) as a white solid 
(299 mg, 77%), m.p = 130-132 °C  1H NMR  (300 MHz, CDCl3): = 0.82 (t, J = 6.8 
Hz, 6H, 2CH3), 1.16-1.35 (m, 12H, 6CH2), 1.58-1.65 (m, 4H, 2CH2), 4.14 (t, 4H, 
2CH2O), 6.49 (d, J = 16.1 Hz, 2H, 2CH), 7.59 (d, J = 16.1 Hz, 2H, 2CH), (brs, 1H, 
ArH), 8.65 (s, 2H, ArH). 13C NMR (75 MHz, CDCl3): = 13.2 (CH3), 21.5, 24.6, 
27.6, 30.4 (CH2), 63.6 (CH2O), 120.5 (CH), 129.3 (C), 131.3, 139.0, 149.3 (CH), 
165.0 (CO). IR (KBr): v = 2954, 2927, 2857 (m), 1712 (s), 1644 (m), 1589, 1566, 
1464, 1421, 1343 (w), 1316 (m), 1258 (s), 1227 (m), 1166 (s), 1068, 1040, 1023 (m), 
993, 980 (s), 903, 866, 857, 794, (m), 613, 603, 545 (w) cm-1. GC-MS (EI, 70 eV): 
m/z (%) = 387 ([M]+, 08), 330 (08), 304 (50), 286 (100), 258 (30), 220 (88), 202 (51), 








(33), 57(100). HRMS (EI, 70 eV): calcd for C19H25O4N 
331.17781 found 331.17831. 
 
(2E,2'E)-Di(tert-butyl) 3,3'-(pyridine-3,5- iyl)diacrylate (23f). Compound 23f was 
prepared starting with 3,5-
dibromopyridine (22), (237 mg, 1.0 
mmol) as a white solid (268 mg, 81%) 
m.p = 135-136 °C.  1H NMR (300 MHz, CDCl3): = 1.47 (s, 18H, 6CH3), 6.41 (d, J 
= 16.1 Hz, 2H, 2CH), 7.49  (d, J = 16.1 Hz, 2H, 2CH), 7.84 (brs, 1H, ArH), 8.62 (s, 
2H, ArH). 13C NMR (62.9 MHz, CDCl3): = 28.0 (CH3), 81.06 (C-O), 123.3 (CH), 
130.5 (C), 132.1, 139.0, 150.1 (CH), 165.2 (CO). IR (KBr): v  = 2974, 2929, 2871 
(m), 1698 (s), 1644 (m), 1573, 1454, 1433 (w), 1391, 1365, 1328, 1295, 1279, 1256 
(m), 1147 (s), 1040, 1025 (w), 970 (s), 857, 848 (m), 807, 782, 761, 724 (w), 687 (m), 
605, 591, 540 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 331 ([M]+, 20), 275 (20), 258 





3,5-Di(2-phenylethenyl)pyridine (23g). Compound 23g was prepared starting with 
3,5-dibromopyridine (22), (237 mg, 1.0 mmol) as a 
white solid (204 mg, 72%), m.p = 115-116 °C 1H NMR 
(300 MHz, CDCl3): = 6.93 (d, J = 16.4 Hz, 2H, 2CH), 
7.08 (d, J = 16.4 Hz, 2H, 2CH), 7.17-7.31 (m, 6H, ArH), 7.39-7.44 (m, 4H, ArH), 
7.78 (s, 1H, ArH), 8.51 (s, 2H, ArH). 13C NMR (75 MHz, CDCl3): = 124.7, 126.8, 
128.25, 128.8, 129.4, 131.1 (CH), 133.1,  136.7 (C), 147.2 (CH). IR (KBr): v  = 3098, 
3080, 3052, 3023, 2926, 2850 (w), 1446 (m), 1414, 1340, 1309, 1239, 1230, 1178, 
1155, 1107, 1023, 999, 983 (w), 962 (s), 919
N
, 892, 825, 833, 797, 779 (w), 745, 691 
(s), 545, 526 (m) cm-1. GC-MS (EI, 70 eV): m/z (%) = 283 ([M]+, 62), 282 (100), 204 
 calcd for C21H17N [M]+: 283.13610; found 
r
 1112, 1041, 1017 (w), 966 (s), 950 (m), 889 (w), 849, 
841 (m), 799 (s), 667, 626 (w) cm-1. GC-MS (EI, 70 eV): m/z (%) = 311 ([M]+, 72), 
10 (100), 294 (10), 170 (6), 154 (12). HRMS (EI, 70 eV): calcd for C23H20N [M-1]+: 
10.15903; found 310.15921. 
(4), 156 (4), 133 (8). HRMS (EI, 70 eV):
283.13699. 
idine (23h). Compound 23h was prepared 
starting with 3,5-dibromopyridine  (22), (237 
mg, 1.0 mmol) as a white solid (236 mg, 
76%), m.p = 118-119 °C  1H NMR (300 
MHz, CDCl3): = 2.30 (s, 6H, 2CH3), 6.93 
(d, J = 16.1 Hz, 2H, 2CH), 7.09-7.14 (m, 6H), 7.37 (d, J = 8.1, 4H, ArH), 7.85 (brs, 
1H, ArH),  8.50 (s, 2H, ArH). 13C NMR (75 MHz, CDCl3): = 21.3 (CH3), 123.6, 
126.7, 129.4, 129.6, 131.1 (CH), 133.2, 133.8, 138.3 (C), 146.6 (CH). IR (KBr): v = 
3038, 3020, 2998, 2912, 2854, 2725 (m), 1603, 1583, 1510, 1462, 1434, 1414, 1371, 
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rystal system  
   2yb 
= 90°. 
 Å = 108.88(3)°. 
1.126(5) Å  = 90°. 
 
 
dependent reflections 999 [R(int) = 0.0754] 
Multiscan 
bsorption coefficient (μ)                              .081 mm-1 
(I)] 56, wR2 = 0.1543 
5, wR2 = 0.1447 




pace group (H.-M.)  
pace group (Hall)  

 
Identification cod AS-107 
Empirical formula  C12H14O2
Formula weight  190.23 
Temperature  173(2) K 
W 0.71073 Å 
C Monoclinic 
Space group (H.-M.)  -P21/m-   
Space group (Hall) -P
Unit cell dimensions a = 506(3) Å 
 b = 6.638(5)
 c = 1
Volume 524.5(5) Å3 
Formula Unit (Z) 2 
Density (calculated) 1.282 Mg/m3 
Absorption coefficient 0.081 mm-1
F (000) 204 
Crystal size 0.37 x 0.28 x 0.28 mm3 




Final R indices [I>2 R1 = 0.06




Identification cod AS-106 
Empirical formula  C18H20O3
Formula weight  284.34 
Temperature  173(2) K 
Wavelength  0
Crystal system  Monoclinic 
S -C21/c-   
S -C2yc 
Unit cell dimensions a = 21.224(5) Å  
 
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=  90°. 
7) Å           = 100.535(14)°.                              
.668(5) Å              = 90°. 
 
 
dependent reflections 9657 [R (int) = 0.0754] 
Multiscan 
oodness-of-fit on F2 1.068 
inal R indices [I>2(I)] R1 = 0.0581, wR2 = 0.1302 
, wR2 = 0.1218 




rystal system  
  ybc- 
Å = 90°. 
9.122(11) Å = 96.902(3)°. 





 b = 7.7457(1
 c = 18
Volume 3017.3(12) Å3 
Formula Unit (Z) 8 
Density (calculated) 1.282 Mg/m3 
Absorption coefficient 0.084 mm-1
F (000) 1216 
Crystal size 0.51 x 0.21 x 0.18 mm3 










Identification co AS-284(b) 
Empirical formula  C19H17O
Formula weight  385.26 
Temperature  173(2) K 
W 0.71073 Å 
C Monoclinic 
Space group (H.-M.)  P21/c-   
Space group (Hall) P 2
Unit cell dimensions a = 9.7394(5) 
 b = 1
 c = 9.6
Volume 1715.06(16)
Formula Uni 4 
Density (calculated) 1.282 M
F (000) 784 
Crystal description                                        Block 
Crystal colour                                                Colourless 
Crystal size 0.25 x 0.20 x 0.8 mm3. 
Reflections collected 19267 
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Independent reflections 4975 [R(int) = 0.0754] 
Multiscan 
bsorption coefficient (μ)                              2.410 mm-1 
(I)] 65, wR2 = 0.0962 
2 = 0.0866 
ound 16e Chapter 3:  
e  
2 F6 S2 
5 
avelength  
rystal system  
   1 
           = 107.228°(7). 
) Å          = 103.169(10)°.                                 





bsorption correction Multiscan 
bsorption coefficient (μ)                              .081 mm-1 
oodness-of-fit on F2 1.045 
inal R indices [I>2(I)] R1 = 0.0522, wR2 = 0.1229 
 indices (all data) R1 = 0.0426, wR2 = 0.1175 
Absorption correction 
A
Final R indices [I>2 R1 = 0.07




Identification cod AS-236 
Empirical formula  C26H16O
Formula weight  506.4
Temperature  173(2) K 
W 0.71073 Å 
C Triclinic 
Space group (H.-M.)   P-1-   
Space group (Hall) P-
Unit cell dimensions a = 6.984(3) Å
 b = 12.824(7
 c = 1
Volume 1094(9)
Formula Unit (Z) 2 
Density (calc 1.282 Mg/m3 
Absorption coefficient 0.222 mm
F (000) 516 
Crystal description                                         Block 
Crystal colour                                                Colorless 
Crystal size 0.85 x 0.35 x 0.13 mm3 
Reflections collected 200371 


















rystal system  




eflections collected 10031 
dependent reflections 2495 [R (int) = 0.0754] 
bsorption correction Tmin 9728, Tmax9958 
inal R indices [I>2(I)] R1 = 0.0655, wR2 = 0.1181 
 indices (all data) R1 = 0.0441, wR2 = 0.1109 
 
Identification cod AS-201 
Empirical formula  C22H28
Formula weight  408.4
Temperature  173(2) K 
W 0.71073 Å 
C Triclinic 
Space group (H.-M.)  -P-1   
Space group (Hall -P
Unit cell dimensions a = 5.761(3) Å
 b = 9.751(5) Å 
 c = 10.180(5) Å  = 78.22°(3). 
Volume 550.2(5) Å3 
FormulaUnit (Z) 1 
Density (calculated) 1.282 Mg/m3 
Absorption coefficient 0.084 mm-1 
F(000) 218 
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